🔗

Mappings

MONDO

MONDO:0010100 Tay-Sachs disease

Orphanet lists MONDO:0010100 as an exact cross-reference for Tay-Sachs disease.

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

Orphanet classifies Tay-Sachs disease as an autosomal recessive disorder.

Autosomal recessive inheritance

Show evidence (1 reference)

ORPHA:845 SUPPORT Other

"Autosomal recessive"

Orphanet directly lists autosomal recessive inheritance for ORPHA:845.

◆

Subtypes

3

Infantile Tay-Sachs

Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5.

Juvenile Tay-Sachs

Onset in childhood, slower progression, death in adolescence.

Late-Onset Tay-Sachs

Adult onset, variable progression, compatible with longer survival.

◈

Mechanistic Hypotheses

1

Canonical HEXA Deficiency / GM2 Ganglioside Neuronal Storage Model

canonical_hexa_gm2_ganglioside_neuronal_storage_model CANONICAL

Tay-Sachs disease is an autosomal recessive lysosomal storage disorder caused by biallelic loss-of- function variants in HEXA on 15q23 encoding the α-subunit of β-hexosaminidase A (αβ heterodimer). Loss of HexA activity prevents lysosomal hydrolysis of GM2 ganglioside, producing massive accumulation of GM2 in lysosomes of central and peripheral neurons. GM2 storage drives ballooned neurons, progressive neuronal death in cerebral cortex, cerebellum, and spinal cord, and secondary microglial activation. Infantile Tay-Sachs (most common, classic) presents at 3-6 months with developmental regression, hyperacusis (exaggerated startle), cherry-red macula, hypotonia, blindness, seizures, and death by age 4. Late-onset (juvenile and adult) forms reflect residual HexA activity and produce slowly progressive cerebellar and motor-neuron-like phenotypes. The cherry-red spot reflects GM2-laden ganglion-cell pallor accentuating the foveolar vasculature. AAV-HEXA gene therapy (TSHA-101 intrathecal) and substrate reduction therapy (miglustat, off-label) are in clinical development; the HEXA mouse model develops GM2 storage but requires Hexa/Hexb double knockout to fully recapitulate the human phenotype, validating the HexA-deficiency / GM2-storage axis as the canonical model.

Retained as CANONICAL. The 2026 openscientist hypothesis-search report (kb/hypotheses/Tay-Sachs_Disease/canonical_hexa_gm2_ganglioside_neuronal_storage_model) finds STRONGLY SUPPORTED — across 57+ papers and 41 evidence items, ZERO refuting evidence was identified. Validated at every level: atomic-resolution HexA crystal structure; genotype-phenotype dose-response (0% residual activity → infantile-lethal; 1.8–4.1% → late-onset cerebellar/motor- neuron); large-animal gene therapy rescue extending survival from 9 months to 5 years. Three refinements: (1) the canonical model does not explain the selective vulnerability of motor neurons and cerebellar Purkinje cells in late-onset forms — neuron-subtype-specific GM2 metabolism or threshold sensitivity remain unresolved; (2) the hierarchical relationship among downstream pathogenic cascades (neuroinflammation, UPR/ER stress, autophagy impairment) remains unresolved — order and relative contribution unknown; (3) the correct infantile-TSD mouse model is Hexa⁻/⁻Neu3⁻/⁻ (not Hexa/Hexb double knockout, which produces additional mucopolysaccharidosis pathology — the seed hypothesis had this incorrectly). Investigational therapies — AAV-HEXA gene therapy (TSHA-101 intrathecal) and substrate reduction (miglustat, off-label) — are in development; no human gene-therapy efficacy data have been published as of 2026.

Deep research

OpenScientist citations 33 citations 2026-05-25T13:40:32.505382

Show evidence (1 reference)

PMID:40710901 SUPPORT Other

"Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."

Existing canonical mechanism citation in the dismech knowledge base, used as the seed for the hypothesis-search deep-research run.

⚙

Pathophysiology

10

HEXA mutations

Biallelic pathogenic variants in HEXA disrupt the alpha subunit of hexosaminidase A. Severe alleles cause the classic infantile enzyme deficiency, while residual-activity alleles can produce later-onset disease.

HEXA link

Downstream

Hexosaminidase A deficiency Loss of functional alpha subunit reduces enzyme activity.

Residual Hexosaminidase A activity in late-onset disease Some pathogenic HEXA alleles, especially G269S, retain residual enzyme activity and shift expression toward late-onset disease.

Show evidence (2 references)

PMID:40710901 SUPPORT Other

"Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."

Review states Tay-Sachs disease is caused by HEXA mutations affecting hexosaminidase A.

PMID:15714079 SUPPORT Human Clinical

"Analysis of the beta-hex A gene revealed the G269S mutation as the most common disease allele; found in homozygosity (N = 1) or heterozygosity (N = 18; including 2 sib pairs)."

Late-onset cohort identifies G269S as the major HEXA allele associated with residual-activity late-onset Tay-Sachs disease.

Hexosaminidase A deficiency

Lysosomal beta-hexosaminidase A enzyme activity is deficient in Tay-Sachs disease.

ganglioside catabolic process link ↓ DECREASED

Downstream

Hexosaminidase A Activity Diagnostic enzyme testing shows absent or reduced hexosaminidase A activity.

GM2 ganglioside accumulation in neurons Reduced catabolism leads to GM2 storage in neurons.

Show evidence (3 references)

PMID:19820796 SUPPORT Human Clinical

"Tay-Sachs disease is an autosomal recessive disorder of sphingolipid metabolism, caused by enzyme hexosaminidase A deficiency that leads to an accumulation of GM2 in neurocytes which results in progressive loss of neurological function."

Supports hexosaminidase A deficiency as a core defect in Tay-Sachs disease.

PMID:36700853 SUPPORT Human Clinical

"We also observed a shift in the expression of the sphingolipid metabolic pathway away from production of the HEXA substrate, GM2 ganglioside, presumptively to compensate for dysfunction of the enzyme."

Fetal-brain transcriptomics shows compensatory remodeling of the sphingolipid metabolic pathway in HEXA-deficient brain, indicating that enzyme dysfunction perturbs sphingolipid metabolism prenatally.

PMID:36700853 SUPPORT Human Clinical

"We identified dramatic changes in the transcriptome, suggesting a perturbation of normal development."

Fetal-brain transcriptomics in HEXA-mutant samples documents dramatic transcriptomic changes consistent with perturbed neurodevelopment preceding overt neurodegeneration.

Residual Hexosaminidase A activity in late-onset disease

Late-onset Tay-Sachs disease is usually associated with at least one HEXA allele that preserves residual beta-hexosaminidase A activity. Partial enzyme activity delays onset but does not prevent progressive neurologic and neuropsychiatric disease.

HEXA link

ganglioside catabolic process link ↓ DECREASED

Downstream

Late-onset cerebellar and anterior motor neuron involvement Residual activity produces a slower phenotype dominated by cerebellar, motor neuron, and psychiatric manifestations.

Show evidence (1 reference)

PMID:15714079 SUPPORT Human Clinical

"In most cases, the later-onset of expression results from the presence of at least one allele (usually the G269S mutation), associated with residual enzyme (beta-hexosaminidase A) activity."

Directly links late-onset disease expression to residual beta-hexosaminidase A activity from alleles such as G269S.

GM2 ganglioside accumulation in neurons

GM2 ganglioside accumulates in neuronal lysosomes, particularly in the brain.

Neuron link

Downstream

GM2 Ganglioside Neuronal storage corresponds to elevated GM2 ganglioside in affected brain tissue.

GM2 Ganglioside Accumulation Neuronal lysosomal storage manifests clinically as GM2-ganglioside accumulation.

Neuroinflammation and Astrogliosis GM2 storage activates microglia and astrocytes, amplifying inflammatory neuronal injury.

Oligodendrocyte loss and demyelination GM2 storage and chronic neuroinflammation are accompanied by reduced oligodendrocyte density and forebrain demyelination.

Neuron death Storage-related toxicity contributes to neuronal loss.

Retinal ganglion cell lipid storage GM2/lipid storage also occurs in retinal ganglion cells, producing the characteristic fundus change.

Macrocephaly Storage-related brain involvement can present with macrocephaly in infantile disease.

Show evidence (1 reference)

PMID:22025593 SUPPORT Human Clinical

"G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."

GM2 gangliosidosis (includes Tay-Sachs) shows ganglioside accumulation in brain.

Neuroinflammation and Astrogliosis

GM2 ganglioside storage is accompanied by activated microglia, astrocyte activation, and inflammatory mediator production that can worsen neuronal injury.

Microglia link Astrocyte link

microglial cell activation link astrocyte activation link neuroinflammatory response link

Downstream

Neuron death Inflammatory glial activation can precede and amplify neuronal loss.

Show evidence (2 references)

PMID:30524313 SUPPORT Other

"Tay-Sachs disease is characterized by acute neurodegeneration preceded by activated microglia expansion, macrophage and astrocyte activation along with inflammatory mediator production."

Review directly links Tay-Sachs neurodegeneration to microglial expansion, astrocyte activation, and inflammatory mediator production.

PMID:23370522 SUPPORT Model Organism

"Recent studies on the molecular pathogenesis in Sandhoff disease patients and disease model mice have shown the involvement of microglial activation and chemokine induction in neuroinflammation and neurodegeneration in this disease."

GM2 gangliosidosis mechanistic studies support microglial activation and chemokine induction as inflammatory contributors to neurodegeneration.

Oligodendrocyte loss and demyelination

GM2 storage and chronic neuroinflammation are accompanied by reduced oligodendrocyte density and reduced forebrain myelination, contributing to white matter loss and the hypomyelination signature seen on infantile Tay-Sachs neuroimaging.

Oligodendrocyte link

myelination link ↓ DECREASED

Downstream

Hypomyelination Reduced oligodendrocyte density and impaired forebrain myelination produce the hypomyelination signature in infantile Tay-Sachs disease.

Show evidence (2 references)

PMID:34456134 SUPPORT Model Organism

"Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density."

Sheep Tay-Sachs natural-history study directly documents widespread reduction in oligodendrocyte density alongside microglial and astrocyte activation.

PMID:34456134 SUPPORT Model Organism

"Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."

Sheep Tay-Sachs model documents reduced forebrain myelination on MRI, supporting the demyelination/hypomyelination mechanism.

Retinal ganglion cell lipid storage

Lipid-filled retinal ganglion cells make the surrounding fundus appear pale, leaving the fovea as a cherry-red macular spot; progressive retinal and central nervous system involvement contributes to visual loss.

Retinal ganglion cell link

lysosome link

Downstream

Cherry-Red Spot Retinal ganglion cell lipid storage creates the chalk-white fundus around the fovea.

Blindness Progressive neuroretinal involvement contributes to vision loss.

Visual Impairment Progressive retinal ganglion cell lipid storage and neuroretinal degeneration produce visual impairment before or short of complete blindness.

Show evidence (1 reference)

PMID:19820796 SUPPORT Human Clinical

"The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."

Directly supports the retinal-ganglion-cell storage mechanism leading to cherry-red spot.

Neuron death

Progressive neuronal loss occurs in the nervous system.

Neuron link

neuron death link

Downstream

Developmental Regression Rapid infantile neurodegeneration causes developmental arrest and loss of attained milestones.

Hypotonia Early neuronal dysfunction presents with hypotonia in infantile GM2 gangliosidosis.

Exaggerated Startle Response Brainstem and auditory pathway dysfunction produces exaggerated startle early in disease.

Seizures Progressive cortical neurodegeneration contributes to epileptic seizures.

Spasticity Progressive upper motor neuron and corticospinal dysfunction contributes to late-stage spasticity.

Dysphagia Progressive bulbar and brainstem dysfunction contributes to swallowing impairment.

Juvenile cerebellar and bulbar involvement Slower childhood-onset neurodegeneration produces cerebellar, bulbar, and motor pathway manifestations.

Show evidence (1 reference)

PMID:29618308 SUPPORT Other

"Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."

Review describes rapid neurodegeneration in infantile GM2 gangliosidosis, consistent with neuronal loss.

Juvenile cerebellar and bulbar involvement

Juvenile Tay-Sachs disease progresses through cerebellar, bulbar, and motor pathway involvement, producing gait, speech, swallowing, tone, and weakness manifestations over childhood.

Neuron link

Downstream

Ataxia Cerebellar involvement produces incoordination and gait disturbance.

Proximal Muscle Weakness Progressive motor involvement contributes to limb weakness and muscle wasting.

Muscle Weakness Progressive motor pathway and anterior motor neuron involvement produce generalized muscle weakness across Tay-Sachs subtypes.

Skeletal Muscle Atrophy Progressive motor involvement produces muscle wasting that corresponds to skeletal muscle atrophy.

Dysarthria Bulbar and motor speech pathway involvement produces dysarthria and speech deterioration.

Dysphagia Bulbar involvement contributes to swallowing impairment in juvenile disease.

Spasticity Progressive motor pathway involvement contributes to increasing tone and spasm progression.

Progressive Spasticity Progressive motor pathway involvement manifests as increasing spasm progression and progressive spasticity.

Cerebellar Atrophy Chronic cerebellar involvement produces cerebellar atrophy on brain MRI in juvenile disease.

Show evidence (2 references)

PMID:17015493 SUPPORT Human Clinical

"The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."

Prospective juvenile GM2 gangliosidosis cohort supports gait, coordination, and speech involvement in juvenile Tay-Sachs disease.

PMID:30524313 SUPPORT Other

"The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."

Review identifies juvenile Tay-Sachs symptoms spanning cerebellar, bulbar, swallowing, tone, and motor manifestations.

Late-onset cerebellar and anterior motor neuron involvement

In late-onset Tay-Sachs disease, chronic residual-activity HEXA disease preferentially manifests with cerebellar dysfunction, anterior motor neuron involvement, and neuropsychiatric episodes rather than the rapid infantile course.

Neuron link

Downstream

Ataxia Cerebellar involvement causes gait and balance impairment.

Proximal Muscle Weakness Anterior motor neuron involvement contributes to progressive proximal weakness.

Cerebellar Atrophy Chronic cerebellar involvement produces marked cerebellar atrophy on neuroimaging in late-onset disease.

Tremor Cerebellar and motor pathway involvement contributes to action tremor and stimulus-sensitive myoclonus in late-onset disease.

Psychosis Late-onset disease can include psychotic episodes and other neuropsychiatric symptoms.

Show evidence (2 references)

PMID:15714079 SUPPORT Human Clinical

"Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."

Cohort conclusion supports cerebellar and anterior motor neuron involvement as the early late-onset phenotype mechanism.

PMID:39807213 SUPPORT Human Clinical

"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."

Recent adult-onset cases confirm the weakness, ataxia, and neuropsychiatric manifestation cluster.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

21

Cardiovascular 1

Cherry-Red Spot VERY_FREQUENT Cherry red spot of the macula (HP:0010729)

Pathognomonic finding on fundoscopy

Show evidence (1 reference)

PMID:19820796 SUPPORT

"The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."

Case report describes cherry-red spot as the hallmark ophthalmologic finding in Tay-Sachs disease.

Digestive 1

Dysphagia FREQUENT Dysphagia (HP:0002015)

Show evidence (3 references)

PMID:30524313 SUPPORT Other

"Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"

Review lists dysphagia among common infantile Tay-Sachs neurodegenerative symptoms.

PMID:17015493 SUPPORT Human Clinical

"However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant."

Juvenile GM2 gangliosidosis natural history documents earlier dysphagia in the Tay-Sachs variant.

ORPHA:845 SUPPORT Other

"HP:0002015 | Dysphagia | Frequent (79-30%)"

Orphanet lists dysphagia as a frequent HPO phenotype for Tay-Sachs disease.

Eye 2

Blindness OCCASIONAL Blindness (HP:0000618)

Progressive visual loss in a subset; visual impairment (HP:0000505) is more frequently observed

Show evidence (2 references)

PMID:24011710 SUPPORT

"Disorders such as Tay-Sachs or Niemann-Pick disease are the most familiar examples of dysfunction in sphingolipid metabolism and are typically associated with neurodegeneration and ocular findings such as blindness."

Review establishes blindness as a characteristic ocular finding in sphingolipidoses including Tay-Sachs disease, though without quantitative frequency data.

ORPHA:845 SUPPORT Other

"HP:0000618 | Blindness | Occasional (29-5%)"

Orphanet lists blindness as occasional for Tay-Sachs disease; visual impairment (HP:0000505) is more common at FREQUENT frequency.

Visual Impairment FREQUENT Visual impairment (HP:0000505)

Show evidence (1 reference)

ORPHA:845 SUPPORT Other

"HP:0000505 | Visual impairment | Frequent (79-30%)"

Orphanet lists visual impairment as a frequent HPO phenotype for Tay-Sachs disease.

Head and Neck 1

Macrocephaly FREQUENT Macrocephaly (HP:0000256)

Due to brain swelling from ganglioside accumulation

Show evidence (1 reference)

PMID:7732608 SUPPORT

"Generalized hypotonia, macrocephaly, hyperacusis and a retinal cherry red spot appearance were present."

Case report documents macrocephaly in Tay-Sachs disease.

Musculoskeletal 6

Hypotonia VERY_FREQUENT Hypotonia (HP:0001252)

Progresses to spasticity

Show evidence (1 reference)

PMID:22025593 SUPPORT

"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."

Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.

Muscle Weakness VERY_FREQUENT Muscle weakness (HP:0001324)

Show evidence (1 reference)

ORPHA:845 SUPPORT Other

"HP:0001324 | Muscle weakness | Very frequent (99-80%)"

Orphanet lists muscle weakness as a very frequent HPO phenotype for Tay-Sachs disease.

Skeletal Muscle Atrophy VERY_FREQUENT Skeletal muscle atrophy (HP:0003202)

Show evidence (1 reference)

ORPHA:845 SUPPORT Other

"HP:0003202 | Skeletal muscle atrophy | Very frequent (99-80%)"

Orphanet lists skeletal muscle atrophy as a very frequent HPO phenotype for Tay-Sachs disease.

Proximal Muscle Weakness Muscle weakness (HP:0001324)

Show evidence (3 references)

PMID:17015493 SUPPORT Human Clinical

"Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."

Juvenile GM2 gangliosidosis natural-history cohort documents later proximal weakness, supporting juvenile Tay-Sachs motor weakness.

PMID:39807213 SUPPORT Human Clinical

"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."

Recent adult-onset cases directly document progressive weakness.

PMID:15714079 SUPPORT Human Clinical

"Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."

Anterior motor neuron involvement mechanistically supports progressive proximal weakness in late-onset disease.

Progressive Spasticity VERY_FREQUENT Progressive spasticity (HP:0002191)

Show evidence (1 reference)

ORPHA:845 SUPPORT Other

"HP:0002191 | Progressive spasticity | Very frequent (99-80%)"

Orphanet lists progressive spasticity as a very frequent HPO phenotype for Tay-Sachs disease.

Spasticity Spasticity (HP:0001257)

Show evidence (2 references)

PMID:30524313 SUPPORT Other

"Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"

Review supports late-stage infantile motor tone/spasm manifestations downstream of neurodegeneration.

PMID:30524313 SUPPORT Other

"The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."

Review supports progressive juvenile motor tone/spasm manifestations.

Nervous System 9

Developmental Regression VERY_FREQUENT Developmental regression (HP:0002376)

Loss of previously acquired milestones, typically starting at 3-6 months

Show evidence (3 references)

PMID:25143775 SUPPORT

"All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression"

Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.

PMID:22025593 SUPPORT

"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."

Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.

PMID:29618308 SUPPORT

"Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."

Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.

Exaggerated Startle Response FREQUENT Exaggerated startle response (HP:0002267)

Hyperacusis with exaggerated startle to sound; prominent in infantile disease (65% in infantile cohorts), lower frequency in aggregate across all subtypes

Show evidence (3 references)

PMID:22025593 SUPPORT

"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."

Natural history study of 97 infantile GM2 gangliosidosis patients confirms exaggerated startle response in 65%, consistent with FREQUENT frequency in the infantile subtype.

PMID:24534057 SUPPORT

"The augmented startle reflex appeared between the age of 3 and 17 months and disappeared between the age of 4 and 6 years."

Electrophysiological study documents the temporal evolution of the augmented startle reflex in Tay-Sachs disease.

ORPHA:845 PARTIAL Other

"HP:0002267 | Exaggerated startle response | Occasional (29-5%)"

Orphanet reports occasional frequency across all subtypes in aggregate; the infantile-specific cohort literature (65%) supports FREQUENT as the appropriate designation for infantile-onset disease.

Seizures OCCASIONAL Seizure (HP:0001250)

Show evidence (2 references)

PMID:25143775 SUPPORT

"38%of patients had a history of developmental delay or regression and 22% had seizures."

Case series documents seizures in 22% of GM2 gangliosidosis patients, consistent with the OCCASIONAL frequency band.

ORPHA:845 SUPPORT Other

"HP:0001250 | Seizure | Occasional (29-5%)"

Orphanet lists seizure as an occasional HPO phenotype for Tay-Sachs disease, consistent with the 22% frequency reported in cohort studies.

Ataxia Ataxia (HP:0001251)

Show evidence (3 references)

PMID:17015493 SUPPORT Human Clinical

"The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."

Juvenile GM2 gangliosidosis cohort documents gait disturbance and incoordination at onset, supporting juvenile Tay-Sachs ataxia.

PMID:15714079 SUPPORT Human Clinical

"Mean age at onset was 18.1 years; balance problems and difficulty climbing stairs were the most frequent presenting complaints."

Late-onset cohort identifies balance problems as a leading presenting complaint, supporting ataxia as a subtype-specific phenotype.

PMID:39807213 SUPPORT Human Clinical

"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."

Adult-onset cases directly document ataxia in late-onset Tay-Sachs disease.

Psychosis OCCASIONAL Psychosis (HP:0000709)

Show evidence (3 references)

PMID:15714079 SUPPORT Human Clinical

"Affected individuals may also develop psychotic episodes."

Cohort conclusion explicitly reports psychotic episodes as part of late-onset Tay-Sachs disease.

PMID:39807213 SUPPORT Human Clinical

"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."

Adult-onset cases support neuropsychiatric involvement in late-onset Tay-Sachs disease.

ORPHA:845 SUPPORT Other

"HP:0000709 | Psychosis | Occasional (29-5%)"

Orphanet lists psychosis as an occasional HPO phenotype for Tay-Sachs disease.

Dysarthria FREQUENT Dysarthria (HP:0001260)

Show evidence (3 references)

PMID:17015493 SUPPORT Human Clinical

"Speech deterioration progressed more rapidly than gait abnormalities in both the Tay-Sachs variant and Sandhoff variant groups."

Juvenile GM2 gangliosidosis natural history documents progressive speech deterioration in the Tay-Sachs variant.

PMID:30524313 SUPPORT Other

"The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."

Review explicitly lists dysarthria among common juvenile Tay-Sachs symptoms.

ORPHA:845 SUPPORT Other

"HP:0001260 | Dysarthria | Frequent (79-30%)"

Orphanet lists dysarthria as a frequent HPO phenotype for Tay-Sachs disease.

Hypomyelination Cerebral hypomyelination (HP:0006808)

Show evidence (2 references)

PMID:30524313 SUPPORT Other

"Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"

Review explicitly lists hypomyelination among common neurodegenerative findings in infantile Tay-Sachs disease.

PMID:34456134 SUPPORT Model Organism

"Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."

Sheep Tay-Sachs natural-history model recapitulates reduced forebrain myelination on MRI.

Cerebellar Atrophy Cerebellar atrophy (HP:0001272)

Show evidence (3 references)

PMID:17015493 SUPPORT Human Clinical

"Cerebellar atrophy was the most common finding on brain MRI (52.9%)."

Juvenile GM2 gangliosidosis natural history identifies cerebellar atrophy as the most common MRI finding.

PMID:15714079 SUPPORT Human Clinical

"Brain imaging studies revealed marked cerebellar atrophy in all patients (N = 18) tested, regardless of disease stage."

Late-onset cohort documents marked cerebellar atrophy in all imaged patients across disease stages.

PMID:28739864 SUPPORT Human Clinical

"MR scan of the brain showed isolated cerebellar atrophy"

Adult-onset Tay-Sachs case report documents isolated cerebellar atrophy on brain MRI.

Tremor Tremor (HP:0001337)

Show evidence (1 reference)

PMID:28739864 SUPPORT Human Clinical

"irregular action tremor and stimulus-sensitive myoclonus of the arms"

Adult-onset Tay-Sachs case report documents irregular action tremor and stimulus-sensitive myoclonus as motor features of late-onset disease.

Other 1

GM2 Ganglioside Accumulation VERY_FREQUENT GM2-ganglioside accumulation (HP:0003495)

Show evidence (1 reference)

ORPHA:845 SUPPORT Other

"HP:0003495 | GM2-ganglioside accumulation | Very frequent (99-80%)"

Orphanet lists GM2-ganglioside accumulation as a very frequent HPO phenotype for Tay-Sachs disease.

🧬

Genetic Associations

1

HEXA (Causative)

Autosomal recessive

Show evidence (3 references)

PMID:40710901 SUPPORT Other

"Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."

Review supports HEXA as the causative gene for Tay-Sachs disease.

PMID:15714079 SUPPORT Human Clinical

"The patients' alpha-subunit mutations (beta-Hexosaminidase A genotype) were determined and correlated with their corresponding clinical findings and disease course."

Late-onset cohort links HEXA alpha-subunit genotypes to clinical disease course.

CGGV:assertion_1f7530b5-af31-40f9-ac18-a1b4d404285a-2020-05-27T160000.000Z SUPPORT Other

ClinGen classifies the HEXA-Tay-Sachs disease gene-disease relationship as definitive with autosomal recessive inheritance.

💊

Treatments

6

Hematopoietic stem cell transplantation (HSCT)

Action: hematopoietic stem cell transplantation MAXO:0000747

HSCT has been investigated as a means of restoring HexA enzyme activity in Tay-Sachs disease. An 8-year longitudinal case in late-onset Tay-Sachs documented normalized HexA enzyme activity and arrested neurodegenerative progression following allogeneic HSCT — the first compelling human evidence that enzyme restoration can halt disease progression. HSCT is not standard of care, has substantial procedure-related risk, and shows limited CNS penetrance, but remains an active area of investigation.

Show evidence (1 reference)

PMID:29214523 SUPPORT Human Clinical

"HSCT is a potential treatment option which might arrest neurodegeneration in patients with LOTS."

8-year longitudinal HSCT case in late-onset Tay-Sachs disease with HexA enzyme normalization and arrested neurodegeneration — first compelling human evidence that enzyme restoration halts disease progression.

Supportive Care

Action: supportive care MAXO:0000950

Symptomatic management including seizure control, nutrition support, respiratory care.

Show evidence (1 reference)

PMID:27491214 SUPPORT

"Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."

Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Carrier screening especially in high-risk populations.

Show evidence (1 reference)

PMID:12108829 SUPPORT

"Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."

Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.

Substrate Reduction Therapy

Action: Pharmacotherapy NCIT:C15986

Investigational approaches to reduce GM2 synthesis using glucose analogs such as miglustat to limit substrate flux into the ganglioside pathway.

Show evidence (2 references)

PMID:27491214 SUPPORT

"Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients."

Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses.

PMID:30524313 SUPPORT Other

"There are also clinical reports of substrate reduction therapy using miglustat and bone marrow or hematopoietic stem cell transplantation."

Review documents miglustat-based substrate reduction therapy as an investigational/off-label option in Tay-Sachs disease.

Pharmacological Chaperone Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: pyrimethamine ↗

Investigational pharmacological chaperones (e.g., pyrimethamine) aim to stabilize residual mutant HEXA folding and trafficking and increase residual hexosaminidase A activity, particularly in mutation-dependent late-onset disease.

Show evidence (1 reference)

PMID:35865957 SUPPORT Other

"This review summarizes multiple drug development strategies for TSD, including enzyme replacement therapy, pharmaceutical chaperone therapy, substrate reduction therapy, gene therapy, and hematopoietic stem cell replacement therapy."

Review of Tay-Sachs therapeutics establishes pharmaceutical chaperone therapy as one of the active drug-development strategies for the disease.

Gene Therapy

Action: gene therapy MAXO:0001001

Experimental AAV-based gene therapy in clinical trials.

Show evidence (1 reference)

PMID:35145305 SUPPORT

"This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy."

First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment.

🔬

Biochemical Markers

2

Hexosaminidase A Activity (Decreased)

Context: Absent or severely reduced in leukocytes or fibroblasts

Pathograph Readouts

Readout Of Hexosaminidase A deficiency Negative Diagnostic

Reduced or absent Hexosaminidase A activity is the diagnostic enzyme readout of the core Tay-Sachs enzyme deficiency.

Show evidence (1 reference)

PMID:40710901 SUPPORT Other

"Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."

Review states that reduced or absent Hexosaminidase A activity is the enzymatic diagnostic basis for Tay-Sachs disease.

Show evidence (1 reference)

PMID:40710901 SUPPORT Other

"Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."

Supports reduced Hexosaminidase A activity as the diagnostic biochemical abnormality.

GM2 Ganglioside (Elevated)

Context: Accumulates in brain tissue

Pathograph Readouts

Readout Of GM2 ganglioside accumulation in neurons Positive Diagnostic

Increased GM2 ganglioside reports lysosomal ganglioside storage in affected neural tissue.

Show evidence (1 reference)

PMID:22025593 SUPPORT Human Clinical

"G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."

Natural-history data link beta-hexosaminidase deficiency to ganglioside accumulation in the brain.

Show evidence (1 reference)

PMID:22025593 SUPPORT Human Clinical

"G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."

Supports elevated GM2/ganglioside storage in affected brain tissue.

🔬

Clinical Trials

2

NCT04798235 PHASE_I ACTIVE_NOT_RECRUITING

Phase 1/2 open-label study evaluating intrathecal TSHA-101 AAV9 gene therapy carrying HEXA and HEXB for infantile-onset GM2 gangliosidosis; ClinicalTrials.gov currently lists the study as active, not recruiting.

Target Phenotypes: Developmental Regression ↗ Seizures ↗

Show evidence (1 reference)

clinicaltrials:NCT04798235 SUPPORT Human Clinical

"The primary purpose of the current study is to assess the safety and tolerability of TSHA101 administered via IT injection."

ClinicalTrials.gov record supports TSHA-101 as an intrathecal gene-therapy trial for infantile-onset GM2 gangliosidosis.

NCT04669535 PHASE_I TERMINATED

Open-label AXO-GM2-001 dose-escalation and safety/efficacy study of bilateral thalamic and intracisternal/intrathecal AXO-AAV-GM2 gene therapy in pediatric Tay-Sachs or Sandhoff disease; ClinicalTrials.gov currently lists the study as terminated.

Target Phenotypes: Developmental Regression ↗ Seizures ↗

Show evidence (1 reference)

clinicaltrials:NCT04669535 SUPPORT Human Clinical

"AXO-AAV-GM2 is an investigational gene therapy that aims to restore HexA function by introducing a functional copy of the HEXA and HEXB genes via co-administration of two vectors utilizing the neurotropic adeno-associated virus recombinant human 8 serotype (AAVrh.8) capsid carrying the human..."

ClinicalTrials.gov record supports AXO-AAV-GM2 as a dual-vector HEXA/HEXB gene-therapy trial relevant to Tay-Sachs disease.

{ }

Source YAML

click to show

name: Tay-Sachs Disease
creation_date: '2026-01-06T04:44:07Z'
updated_date: '2026-05-21T02:19:10Z'
category: Genetic
parents:
- Lysosomal Storage Disorder
- Neurodegenerative Disease
disease_term:
  preferred_term: Tay-Sachs disease
  term:
    id: MONDO:0010100
    label: Tay-Sachs disease
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010100
      label: Tay-Sachs disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:845
    mapping_justification: Orphanet lists MONDO:0010100 as an exact cross-reference for Tay-Sachs disease.
    consistency:
    - reference: ORPHA:845
      consistent: CONSISTENT
      notes: "MONDO:0010100 | Exact"
external_assertions:
- name: Orphanet Tay-Sachs disease record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:845
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=845
  description: >-
    Orphanet curates ORPHA:845 as the Tay-Sachs disease disorder record and
    provides structured synonyms, definition, inheritance, natural history,
    epidemiology, HPO phenotype frequencies, and cross-references.
  notes: >-
    ORPHA:845 lists exact cross-references to MONDO:0010100, MeSH:D013661,
    MedDRA:10043147, OMIM:272800, and UMLS:C0039373, with
    narrower ICD-10:E75.0 and ICD-11:5C56.00 rows.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:845  Tay-Sachs disease"
    explanation: The structured cache heading identifies ORPHA:845 as the Orphanet Tay-Sachs disease record.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0010100 | Exact"
    explanation: Orphanet maps ORPHA:845 exactly to the MONDO disease identifier used by this entry.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:272800 | Exact"
    explanation: Orphanet lists OMIM:272800 as an exact cross-reference for Tay-Sachs disease.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MeSH:D013661 | Exact"
    explanation: Orphanet lists MeSH:D013661 as an exact cross-reference for Tay-Sachs disease.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: Orphanet classifies Tay-Sachs disease as an autosomal recessive disorder.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet directly lists autosomal recessive inheritance for ORPHA:845.
progression:
- phase: Age of onset
  age_range: All ages
  notes: Orphanet records onset across all ages, consistent with infantile, juvenile, and late-onset clinical subtypes.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: All ages"
    explanation: Orphanet's natural-history section records Tay-Sachs disease onset as occurring across all ages.
has_subtypes:
- name: Infantile Tay-Sachs
  description: Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5.
- name: Juvenile Tay-Sachs
  description: Onset in childhood, slower progression, death in adolescence.
- name: Late-Onset Tay-Sachs
  description: Adult onset, variable progression, compatible with longer survival.
prevalence:
- population: Ashkenazi Jewish population
  percentage: 1 in 3,500 newborns
  notes: >-
    Tay-Sachs disease has historically been far more common in Ashkenazi Jewish
    populations than in the general population. Community carrier screening and
    prenatal diagnosis programs reduced incidence in Jewish populations in the
    United States and Canada by more than 90%.
  evidence:
  - reference: PMID:11500789
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Ashkenazi Jewish population the disease incidence is about 1 in every 3,500 newborns and the carrier frequency is 1 in every 29 individuals."
    explanation: This study directly reports the historically high Tay-Sachs disease incidence in the Ashkenazi Jewish population.
  - reference: PMID:11216898
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the United States and Canada, the incidence of TSD in the Jewish population has been reduced by more than 90%."
    explanation: This review shows that the historically high disease burden in Jewish populations fell substantially after population carrier screening.
- population: Worldwide live births
  percentage: "1-9 / 1 000 000 prevalence at birth"
  notes: Orphanet reports a worldwide prevalence-at-birth class of 1-9 per 1,000,000.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Worldwide | Prevalence at birth | PMID:0870684507"
    explanation: The Orphanet epidemiology table provides the worldwide prevalence-at-birth class for Tay-Sachs disease.
- population: Specific population live births
  percentage: "1-5 / 10 000 prevalence at birth"
  notes: Orphanet records a higher prevalence-at-birth class in a specific population.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Specific population | Prevalence at birth | PMID:20301397"
    explanation: The Orphanet epidemiology table records a higher prevalence-at-birth class for a specific population.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_hexa_gm2_ganglioside_neuronal_storage_model
  hypothesis_label: Canonical HEXA Deficiency / GM2 Ganglioside Neuronal Storage Model
  status: CANONICAL
  description: >-
    Tay-Sachs disease is an autosomal recessive lysosomal storage disorder caused by biallelic loss-of-
    function variants in HEXA on 15q23 encoding the α-subunit of β-hexosaminidase A (αβ heterodimer).
    Loss of HexA activity prevents lysosomal hydrolysis of GM2 ganglioside, producing massive
    accumulation of GM2 in lysosomes of central and peripheral neurons. GM2 storage drives ballooned
    neurons, progressive neuronal death in cerebral cortex, cerebellum, and spinal cord, and secondary
    microglial activation. Infantile Tay-Sachs (most common, classic) presents at 3-6 months with
    developmental regression, hyperacusis (exaggerated startle), cherry-red macula, hypotonia,
    blindness, seizures, and death by age 4. Late-onset (juvenile and adult) forms reflect residual HexA
    activity and produce slowly progressive cerebellar and motor-neuron-like phenotypes. The cherry-red
    spot reflects GM2-laden ganglion-cell pallor accentuating the foveolar vasculature. AAV-HEXA gene
    therapy (TSHA-101 intrathecal) and substrate reduction therapy (miglustat, off-label) are in
    clinical development; the HEXA mouse model develops GM2 storage but requires Hexa/Hexb double
    knockout to fully recapitulate the human phenotype, validating the HexA-deficiency / GM2-storage
    axis as the canonical model.
  notes: >-
    Retained as CANONICAL. The 2026 openscientist
    hypothesis-search report
    (kb/hypotheses/Tay-Sachs_Disease/canonical_hexa_gm2_ganglioside_neuronal_storage_model)
    finds STRONGLY SUPPORTED — across 57+ papers and 41 evidence
    items, ZERO refuting evidence was identified. Validated at
    every level: atomic-resolution HexA crystal structure;
    genotype-phenotype dose-response (0% residual activity →
    infantile-lethal; 1.8–4.1% → late-onset cerebellar/motor-
    neuron); large-animal gene therapy rescue extending survival
    from 9 months to 5 years. Three refinements: (1) the
    canonical model does not explain the selective vulnerability
    of motor neurons and cerebellar Purkinje cells in late-onset
    forms — neuron-subtype-specific GM2 metabolism or threshold
    sensitivity remain unresolved; (2) the hierarchical
    relationship among downstream pathogenic cascades
    (neuroinflammation, UPR/ER stress, autophagy impairment)
    remains unresolved — order and relative contribution
    unknown; (3) the correct infantile-TSD mouse model is
    Hexa⁻/⁻Neu3⁻/⁻ (not Hexa/Hexb double knockout, which
    produces additional mucopolysaccharidosis pathology — the
    seed hypothesis had this incorrectly). Investigational
    therapies — AAV-HEXA gene therapy (TSHA-101 intrathecal) and
    substrate reduction (miglustat, off-label) — are in
    development; no human gene-therapy efficacy data have been
    published as of 2026.
  evidence:
  - reference: PMID:40710901
    reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
    explanation: >
      Existing canonical mechanism citation in the dismech
      knowledge base, used as the seed for the hypothesis-search
      deep-research run.
pathophysiology:
- name: HEXA mutations
  description: >
    Biallelic pathogenic variants in HEXA disrupt the alpha subunit of
    hexosaminidase A. Severe alleles cause the classic infantile enzyme
    deficiency, while residual-activity alleles can produce later-onset disease.
  genes:
  - preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  downstream:
  - target: Hexosaminidase A deficiency
    description: Loss of functional alpha subunit reduces enzyme activity.
    causal_link_type: DIRECT
  - target: Residual Hexosaminidase A activity in late-onset disease
    description: Some pathogenic HEXA alleles, especially G269S, retain residual enzyme activity and shift expression toward late-onset disease.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:40710901
    reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
    explanation: Review states Tay-Sachs disease is caused by HEXA mutations affecting hexosaminidase A.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of the beta-hex A gene revealed the G269S mutation as the most common disease allele; found in homozygosity (N = 1) or heterozygosity (N = 18; including 2 sib pairs)."
    explanation: Late-onset cohort identifies G269S as the major HEXA allele associated with residual-activity late-onset Tay-Sachs disease.
- name: Hexosaminidase A deficiency
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Hydrolase or Cofactor Deficiency"
  description: >
    Lysosomal beta-hexosaminidase A enzyme activity is deficient in Tay-Sachs disease.
  biological_processes:
  - preferred_term: ganglioside catabolic process
    modifier: DECREASED
    term:
      id: GO:0006689
      label: ganglioside catabolic process
  downstream:
  - target: Hexosaminidase A Activity
    description: Diagnostic enzyme testing shows absent or reduced hexosaminidase A activity.
    causal_link_type: DIRECT
  - target: GM2 ganglioside accumulation in neurons
    description: Reduced catabolism leads to GM2 storage in neurons.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tay-Sachs disease is an autosomal recessive disorder of sphingolipid metabolism, caused by enzyme hexosaminidase A deficiency that leads to an accumulation of GM2 in neurocytes which results in progressive loss of neurological function."
    explanation: Supports hexosaminidase A deficiency as a core defect in Tay-Sachs disease.
  - reference: PMID:36700853
    reference_title: "Gene expression changes in Tay-Sachs disease begin early in fetal brain development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also observed a shift in the expression of the sphingolipid metabolic pathway away from production of the HEXA substrate, GM2 ganglioside, presumptively to compensate for dysfunction of the enzyme."
    explanation: Fetal-brain transcriptomics shows compensatory remodeling of the sphingolipid metabolic pathway in HEXA-deficient brain, indicating that enzyme dysfunction perturbs sphingolipid metabolism prenatally.
  - reference: PMID:36700853
    reference_title: "Gene expression changes in Tay-Sachs disease begin early in fetal brain development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified dramatic changes in the transcriptome, suggesting a perturbation of normal development."
    explanation: Fetal-brain transcriptomics in HEXA-mutant samples documents dramatic transcriptomic changes consistent with perturbed neurodevelopment preceding overt neurodegeneration.
- name: Residual Hexosaminidase A activity in late-onset disease
  description: >
    Late-onset Tay-Sachs disease is usually associated with at least one HEXA
    allele that preserves residual beta-hexosaminidase A activity. Partial
    enzyme activity delays onset but does not prevent progressive neurologic and
    neuropsychiatric disease.
  subtypes:
  - Late-Onset Tay-Sachs
  genes:
  - preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  biological_processes:
  - preferred_term: ganglioside catabolic process
    modifier: DECREASED
    term:
      id: GO:0006689
      label: ganglioside catabolic process
  downstream:
  - target: Late-onset cerebellar and anterior motor neuron involvement
    description: Residual activity produces a slower phenotype dominated by cerebellar, motor neuron, and psychiatric manifestations.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic neuronal GM2 storage
    - progressive cerebellar atrophy
  evidence:
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In most cases, the later-onset of expression results from the presence of at least one allele (usually the G269S mutation), associated with residual enzyme (beta-hexosaminidase A) activity."
    explanation: Directly links late-onset disease expression to residual beta-hexosaminidase A activity from alleles such as G269S.
- name: GM2 ganglioside accumulation in neurons
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >
    GM2 ganglioside accumulates in neuronal lysosomes, particularly in the brain.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: GM2 Ganglioside
    description: Neuronal storage corresponds to elevated GM2 ganglioside in affected brain tissue.
    causal_link_type: DIRECT
  - target: GM2 Ganglioside Accumulation
    description: Neuronal lysosomal storage manifests clinically as GM2-ganglioside accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:845
      reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003495 | GM2-ganglioside accumulation | Very frequent (99-80%)"
      explanation: Orphanet lists GM2-ganglioside accumulation as a very frequent Tay-Sachs phenotype, matching the neuronal storage mechanism.
  - target: Neuroinflammation and Astrogliosis
    description: GM2 storage activates microglia and astrocytes, amplifying inflammatory neuronal injury.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal storage stress
    - activated microglia expansion
    - astrocyte activation
  - target: Oligodendrocyte loss and demyelination
    description: GM2 storage and chronic neuroinflammation are accompanied by reduced oligodendrocyte density and forebrain demyelination.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal storage stress
    - microglial activation
    - oligodendrocyte injury
  - target: Neuron death
    description: Storage-related toxicity contributes to neuronal loss.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal storage stress
    - neuronal dysfunction
  - target: Retinal ganglion cell lipid storage
    description: GM2/lipid storage also occurs in retinal ganglion cells, producing the characteristic fundus change.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal lipid accumulation
  - target: Macrocephaly
    description: Storage-related brain involvement can present with macrocephaly in infantile disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neuronal lysosomal storage
    - brain enlargement
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
    explanation: GM2 gangliosidosis (includes Tay-Sachs) shows ganglioside accumulation in brain.
- name: Neuroinflammation and Astrogliosis
  description: >
    GM2 ganglioside storage is accompanied by activated microglia, astrocyte
    activation, and inflammatory mediator production that can worsen neuronal
    injury.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
  - preferred_term: astrocyte activation
    term:
      id: GO:0048143
      label: astrocyte activation
  - preferred_term: neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  downstream:
  - target: Neuron death
    description: Inflammatory glial activation can precede and amplify neuronal loss.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - inflammatory mediator production
    - chemokine induction
    - activated glial crosstalk
  evidence:
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Tay-Sachs disease is characterized by acute neurodegeneration preceded by activated microglia expansion, macrophage and astrocyte activation along with inflammatory mediator production."
    explanation: Review directly links Tay-Sachs neurodegeneration to microglial expansion, astrocyte activation, and inflammatory mediator production.
  - reference: PMID:23370522
    reference_title: "[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis]."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Recent studies on the molecular pathogenesis in Sandhoff disease patients and disease model mice have shown the involvement of microglial activation and chemokine induction in neuroinflammation and neurodegeneration in this disease."
    explanation: GM2 gangliosidosis mechanistic studies support microglial activation and chemokine induction as inflammatory contributors to neurodegeneration.
- name: Oligodendrocyte loss and demyelination
  description: >
    GM2 storage and chronic neuroinflammation are accompanied by reduced
    oligodendrocyte density and reduced forebrain myelination, contributing to
    white matter loss and the hypomyelination signature seen on infantile Tay-Sachs
    neuroimaging.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    modifier: DECREASED
    term:
      id: GO:0042552
      label: myelination
  downstream:
  - target: Hypomyelination
    description: Reduced oligodendrocyte density and impaired forebrain myelination produce the hypomyelination signature in infantile Tay-Sachs disease.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34456134
    reference_title: "Natural history of Tay-Sachs disease in sheep."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density."
    explanation: Sheep Tay-Sachs natural-history study directly documents widespread reduction in oligodendrocyte density alongside microglial and astrocyte activation.
  - reference: PMID:34456134
    reference_title: "Natural history of Tay-Sachs disease in sheep."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
    explanation: Sheep Tay-Sachs model documents reduced forebrain myelination on MRI, supporting the demyelination/hypomyelination mechanism.
- name: Retinal ganglion cell lipid storage
  description: >
    Lipid-filled retinal ganglion cells make the surrounding fundus appear pale,
    leaving the fovea as a cherry-red macular spot; progressive retinal and
    central nervous system involvement contributes to visual loss.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  downstream:
  - target: Cherry-Red Spot
    description: Retinal ganglion cell lipid storage creates the chalk-white fundus around the fovea.
    causal_link_type: DIRECT
  - target: Blindness
    description: Progressive neuroretinal involvement contributes to vision loss.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - retinal ganglion cell dysfunction
    - neurodegeneration
  - target: Visual Impairment
    description: Progressive retinal ganglion cell lipid storage and neuroretinal degeneration produce visual impairment before or short of complete blindness.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - retinal ganglion cell dysfunction
    - neurodegeneration
    evidence:
    - reference: ORPHA:845
      reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000505 | Visual impairment | Frequent (79-30%)"
      explanation: Orphanet lists visual impairment as a frequent Tay-Sachs phenotype, consistent with retinal ganglion cell lipid storage.
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
    explanation: Directly supports the retinal-ganglion-cell storage mechanism leading to cherry-red spot.
- name: Neuron death
  description: >
    Progressive neuronal loss occurs in the nervous system.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron death
    term:
      id: GO:0051402
      label: neuron apoptotic process
  downstream:
  - target: Developmental Regression
    description: Rapid infantile neurodegeneration causes developmental arrest and loss of attained milestones.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - developmental arrest
    - loss of attained milestones
  - target: Hypotonia
    description: Early neuronal dysfunction presents with hypotonia in infantile GM2 gangliosidosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
  - target: Exaggerated Startle Response
    description: Brainstem and auditory pathway dysfunction produces exaggerated startle early in disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - brainstem hyperexcitability
  - target: Seizures
    description: Progressive cortical neurodegeneration contributes to epileptic seizures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cortical neuronal dysfunction
  - target: Spasticity
    description: Progressive upper motor neuron and corticospinal dysfunction contributes to late-stage spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron involvement
  - target: Dysphagia
    description: Progressive bulbar and brainstem dysfunction contributes to swallowing impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar motor dysfunction
    - brainstem involvement
  - target: Juvenile cerebellar and bulbar involvement
    description: Slower childhood-onset neurodegeneration produces cerebellar, bulbar, and motor pathway manifestations.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic neuronal GM2 storage
    - progressive cerebellar involvement
    - bulbar motor dysfunction
  evidence:
  - reference: PMID:29618308
    reference_title: "Genetics and Therapies for GM2 Gangliosidosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
    explanation: Review describes rapid neurodegeneration in infantile GM2 gangliosidosis, consistent with neuronal loss.
- name: Juvenile cerebellar and bulbar involvement
  description: >
    Juvenile Tay-Sachs disease progresses through cerebellar, bulbar, and motor
    pathway involvement, producing gait, speech, swallowing, tone, and weakness
    manifestations over childhood.
  subtypes:
  - Juvenile Tay-Sachs
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Ataxia
    description: Cerebellar involvement produces incoordination and gait disturbance.
    causal_link_type: DIRECT
  - target: Proximal Muscle Weakness
    description: Progressive motor involvement contributes to limb weakness and muscle wasting.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
    - muscle wasting
  - target: Muscle Weakness
    description: Progressive motor pathway and anterior motor neuron involvement produce generalized muscle weakness across Tay-Sachs subtypes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
    - anterior motor neuron involvement
    evidence:
    - reference: PMID:17015493
      reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
      explanation: Juvenile GM2 gangliosidosis natural history documents proximal weakness during disease progression.
  - target: Skeletal Muscle Atrophy
    description: Progressive motor involvement produces muscle wasting that corresponds to skeletal muscle atrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
    - anterior motor neuron involvement
    evidence:
    - reference: PMID:17015493
      reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
      explanation: The juvenile GM2 gangliosidosis natural-history cohort directly reports muscle wasting during disease progression.
  - target: Dysarthria
    description: Bulbar and motor speech pathway involvement produces dysarthria and speech deterioration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar motor dysfunction
    - motor speech impairment
  - target: Dysphagia
    description: Bulbar involvement contributes to swallowing impairment in juvenile disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar motor dysfunction
  - target: Spasticity
    description: Progressive motor pathway involvement contributes to increasing tone and spasm progression.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron involvement
  - target: Progressive Spasticity
    description: Progressive motor pathway involvement manifests as increasing spasm progression and progressive spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron involvement
    evidence:
    - reference: PMID:30524313
      reference_title: "New Approaches to Tay-Sachs Disease Therapy."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."
      explanation: The review lists spasm progression among common juvenile Tay-Sachs symptoms, supporting progressive spasticity downstream of motor pathway involvement.
  - target: Cerebellar Atrophy
    description: Chronic cerebellar involvement produces cerebellar atrophy on brain MRI in juvenile disease.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
    explanation: Prospective juvenile GM2 gangliosidosis cohort supports gait, coordination, and speech involvement in juvenile Tay-Sachs disease.
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."
    explanation: Review identifies juvenile Tay-Sachs symptoms spanning cerebellar, bulbar, swallowing, tone, and motor manifestations.
- name: Late-onset cerebellar and anterior motor neuron involvement
  description: >
    In late-onset Tay-Sachs disease, chronic residual-activity HEXA disease
    preferentially manifests with cerebellar dysfunction, anterior motor neuron
    involvement, and neuropsychiatric episodes rather than the rapid infantile
    course.
  subtypes:
  - Late-Onset Tay-Sachs
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Ataxia
    description: Cerebellar involvement causes gait and balance impairment.
    causal_link_type: DIRECT
  - target: Proximal Muscle Weakness
    description: Anterior motor neuron involvement contributes to progressive proximal weakness.
    causal_link_type: DIRECT
  - target: Cerebellar Atrophy
    description: Chronic cerebellar involvement produces marked cerebellar atrophy on neuroimaging in late-onset disease.
    causal_link_type: DIRECT
  - target: Tremor
    description: Cerebellar and motor pathway involvement contributes to action tremor and stimulus-sensitive myoclonus in late-onset disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar dysfunction
    - motor pathway involvement
  - target: Psychosis
    description: Late-onset disease can include psychotic episodes and other neuropsychiatric symptoms.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neuropsychiatric involvement
  evidence:
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
    explanation: Cohort conclusion supports cerebellar and anterior motor neuron involvement as the early late-onset phenotype mechanism.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Recent adult-onset cases confirm the weakness, ataxia, and neuropsychiatric manifestation cluster.
phenotypes:
- name: Developmental Regression
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Loss of previously acquired milestones, typically starting at 3-6 months
  phenotype_term:
    preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:25143775
    reference_title: "GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series)."
    supports: SUPPORT
    snippet: "All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression"
    explanation: Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.
  - reference: PMID:29618308
    reference_title: "Genetics and Therapies for GM2 Gangliosidosis."
    supports: SUPPORT
    snippet: "Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
    explanation: Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.
- name: Cherry-Red Spot
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Pathognomonic finding on fundoscopy
  phenotype_term:
    preferred_term: Cherry-Red Spot
    term:
      id: HP:0010729
      label: Cherry red spot of the macula
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    snippet: "The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
    explanation: Case report describes cherry-red spot as the hallmark ophthalmologic finding in Tay-Sachs disease.
- name: Exaggerated Startle Response
  category: Neurological
  frequency: FREQUENT
  notes: Hyperacusis with exaggerated startle to sound; prominent in infantile disease (65% in infantile cohorts), lower frequency in aggregate across all subtypes
  phenotype_term:
    preferred_term: Exaggerated Startle Response
    term:
      id: HP:0002267
      label: Exaggerated startle response
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study of 97 infantile GM2 gangliosidosis patients confirms exaggerated startle response in 65%, consistent with FREQUENT frequency in the infantile subtype.
  - reference: PMID:24534057
    reference_title: "Correlation of augmented startle reflex with brainstem electrophysiological responses in Tay-Sachs disease."
    supports: SUPPORT
    snippet: "The augmented startle reflex appeared between the age of 3 and 17 months and disappeared between the age of 4 and 6 years."
    explanation: Electrophysiological study documents the temporal evolution of the augmented startle reflex in Tay-Sachs disease.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "HP:0002267 | Exaggerated startle response | Occasional (29-5%)"
    explanation: Orphanet reports occasional frequency across all subtypes in aggregate; the infantile-specific cohort literature (65%) supports FREQUENT as the appropriate designation for infantile-onset disease.
- name: Hypotonia
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Progresses to spasticity
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.
- name: Seizures
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:25143775
    reference_title: "GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series)."
    supports: SUPPORT
    snippet: "38%of patients had a history of developmental delay or regression and 22% had seizures."
    explanation: Case series documents seizures in 22% of GM2 gangliosidosis patients, consistent with the OCCASIONAL frequency band.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
    explanation: Orphanet lists seizure as an occasional HPO phenotype for Tay-Sachs disease, consistent with the 22% frequency reported in cohort studies.
- name: Macrocephaly
  category: Neurological
  frequency: FREQUENT
  notes: Due to brain swelling from ganglioside accumulation
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:7732608
    reference_title: "Tay-Sachs disease: a case report."
    supports: SUPPORT
    snippet: "Generalized hypotonia, macrocephaly, hyperacusis and a retinal cherry red spot appearance were present."
    explanation: Case report documents macrocephaly in Tay-Sachs disease.
- name: Blindness
  category: Ophthalmologic
  frequency: OCCASIONAL
  notes: Progressive visual loss in a subset; visual impairment (HP:0000505) is more frequently observed
  phenotype_term:
    preferred_term: Blindness
    term:
      id: HP:0000618
      label: Blindness
  evidence:
  - reference: PMID:24011710
    reference_title: "Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders."
    supports: SUPPORT
    snippet: "Disorders such as Tay-Sachs or Niemann-Pick disease are the most familiar examples of dysfunction in sphingolipid metabolism and are typically associated with neurodegeneration and ocular findings such as blindness."
    explanation: Review establishes blindness as a characteristic ocular finding in sphingolipidoses including Tay-Sachs disease, though without quantitative frequency data.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000618 | Blindness | Occasional (29-5%)"
    explanation: Orphanet lists blindness as occasional for Tay-Sachs disease; visual impairment (HP:0000505) is more common at FREQUENT frequency.
- name: Visual Impairment
  category: Ophthalmologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Visual Impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000505 | Visual impairment | Frequent (79-30%)"
    explanation: Orphanet lists visual impairment as a frequent HPO phenotype for Tay-Sachs disease.
- name: Ataxia
  category: Neurological
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: Gait and balance impairment are common presenting features of juvenile and late-onset Tay-Sachs disease.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
    explanation: Juvenile GM2 gangliosidosis cohort documents gait disturbance and incoordination at onset, supporting juvenile Tay-Sachs ataxia.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean age at onset was 18.1 years; balance problems and difficulty climbing stairs were the most frequent presenting complaints."
    explanation: Late-onset cohort identifies balance problems as a leading presenting complaint, supporting ataxia as a subtype-specific phenotype.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Adult-onset cases directly document ataxia in late-onset Tay-Sachs disease.
- name: Muscle Weakness
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Muscle Weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001324 | Muscle weakness | Very frequent (99-80%)"
    explanation: Orphanet lists muscle weakness as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Skeletal Muscle Atrophy
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Skeletal Muscle Atrophy
    term:
      id: HP:0003202
      label: Skeletal muscle atrophy
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003202 | Skeletal muscle atrophy | Very frequent (99-80%)"
    explanation: Orphanet lists skeletal muscle atrophy as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Proximal Muscle Weakness
  category: Neurological
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: Progressive proximal weakness reflects motor neuron and motor pathway involvement in juvenile and late-onset disease.
  phenotype_term:
    preferred_term: Proximal Muscle Weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
    explanation: Juvenile GM2 gangliosidosis natural-history cohort documents later proximal weakness, supporting juvenile Tay-Sachs motor weakness.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Recent adult-onset cases directly document progressive weakness.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
    explanation: Anterior motor neuron involvement mechanistically supports progressive proximal weakness in late-onset disease.
- name: Psychosis
  category: Neuropsychiatric
  frequency: OCCASIONAL
  subtypes:
  - Late-Onset Tay-Sachs
  description: Psychotic episodes and other neuropsychiatric symptoms can dominate late-onset Tay-Sachs disease in some patients.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  evidence:
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals may also develop psychotic episodes."
    explanation: Cohort conclusion explicitly reports psychotic episodes as part of late-onset Tay-Sachs disease.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Adult-onset cases support neuropsychiatric involvement in late-onset Tay-Sachs disease.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000709 | Psychosis | Occasional (29-5%)"
    explanation: Orphanet lists psychosis as an occasional HPO phenotype for Tay-Sachs disease.
- name: Progressive Spasticity
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Progressive Spasticity
    term:
      id: HP:0002191
      label: Progressive spasticity
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002191 | Progressive spasticity | Very frequent (99-80%)"
    explanation: Orphanet lists progressive spasticity as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Spasticity
  category: Neurological
  subtypes:
  - Infantile Tay-Sachs
  - Juvenile Tay-Sachs
  description: Progressive motor pathway involvement can produce late infantile spasticity and juvenile spasm progression.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"
    explanation: Review supports late-stage infantile motor tone/spasm manifestations downstream of neurodegeneration.
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."
    explanation: Review supports progressive juvenile motor tone/spasm manifestations.
- name: Dysarthria
  category: Neurological
  frequency: FREQUENT
  subtypes:
  - Juvenile Tay-Sachs
  description: Motor speech impairment is part of the juvenile Tay-Sachs clinical course.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Speech deterioration progressed more rapidly than gait abnormalities in both the Tay-Sachs variant and Sandhoff variant groups."
    explanation: Juvenile GM2 gangliosidosis natural history documents progressive speech deterioration in the Tay-Sachs variant.
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."
    explanation: Review explicitly lists dysarthria among common juvenile Tay-Sachs symptoms.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001260 | Dysarthria | Frequent (79-30%)"
    explanation: Orphanet lists dysarthria as a frequent HPO phenotype for Tay-Sachs disease.
- name: Dysphagia
  category: Neurological
  frequency: FREQUENT
  subtypes:
  - Infantile Tay-Sachs
  - Juvenile Tay-Sachs
  description: Swallowing dysfunction occurs in infantile and juvenile Tay-Sachs disease as neurodegeneration progresses.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"
    explanation: Review lists dysphagia among common infantile Tay-Sachs neurodegenerative symptoms.
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant."
    explanation: Juvenile GM2 gangliosidosis natural history documents earlier dysphagia in the Tay-Sachs variant.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002015 | Dysphagia | Frequent (79-30%)"
    explanation: Orphanet lists dysphagia as a frequent HPO phenotype for Tay-Sachs disease.
- name: GM2 Ganglioside Accumulation
  category: Biochemical
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: GM2 Ganglioside Accumulation
    term:
      id: HP:0003495
      label: GM2-ganglioside accumulation
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003495 | GM2-ganglioside accumulation | Very frequent (99-80%)"
    explanation: Orphanet lists GM2-ganglioside accumulation as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Hypomyelination
  category: Neurological
  subtypes:
  - Infantile Tay-Sachs
  description: Reduced myelination is part of the infantile Tay-Sachs neurodegenerative phenotype, reflecting oligodendrocyte loss and impaired forebrain myelination.
  phenotype_term:
    preferred_term: Cerebral hypomyelination
    term:
      id: HP:0006808
      label: Cerebral hypomyelination
  evidence:
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"
    explanation: Review explicitly lists hypomyelination among common neurodegenerative findings in infantile Tay-Sachs disease.
  - reference: PMID:34456134
    reference_title: "Natural history of Tay-Sachs disease in sheep."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
    explanation: Sheep Tay-Sachs natural-history model recapitulates reduced forebrain myelination on MRI.
- name: Cerebellar Atrophy
  category: Neurological
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: Cerebellar atrophy is the most common neuroimaging finding in juvenile and late-onset Tay-Sachs disease and may be present even when focal neurologic deficits are subtle.
  phenotype_term:
    preferred_term: Cerebellar Atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar atrophy was the most common finding on brain MRI (52.9%)."
    explanation: Juvenile GM2 gangliosidosis natural history identifies cerebellar atrophy as the most common MRI finding.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain imaging studies revealed marked cerebellar atrophy in all patients (N = 18) tested, regardless of disease stage."
    explanation: Late-onset cohort documents marked cerebellar atrophy in all imaged patients across disease stages.
  - reference: PMID:28739864
    reference_title: "Late-onset Tay-Sachs disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MR scan of the brain showed isolated cerebellar atrophy"
    explanation: Adult-onset Tay-Sachs case report documents isolated cerebellar atrophy on brain MRI.
- name: Tremor
  category: Neurological
  subtypes:
  - Late-Onset Tay-Sachs
  description: Action tremor and stimulus-sensitive myoclonus can be part of the late-onset Tay-Sachs disease motor phenotype.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:28739864
    reference_title: "Late-onset Tay-Sachs disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "irregular action tremor and stimulus-sensitive myoclonus of the arms"
    explanation: Adult-onset Tay-Sachs case report documents irregular action tremor and stimulus-sensitive myoclonus as motor features of late-onset disease.
biochemical:
- name: Hexosaminidase A Activity
  presence: Decreased
  context: Absent or severely reduced in leukocytes or fibroblasts
  readouts:
  - target: Hexosaminidase A deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Reduced or absent Hexosaminidase A activity is the diagnostic enzyme readout of the core Tay-Sachs enzyme deficiency.
    evidence:
    - reference: PMID:40710901
      reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."
      explanation: Review states that reduced or absent Hexosaminidase A activity is the enzymatic diagnostic basis for Tay-Sachs disease.
  evidence:
  - reference: PMID:40710901
    reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."
    explanation: Supports reduced Hexosaminidase A activity as the diagnostic biochemical abnormality.
- name: GM2 Ganglioside
  presence: Elevated
  context: Accumulates in brain tissue
  readouts:
  - target: GM2 ganglioside accumulation in neurons
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Increased GM2 ganglioside reports lysosomal ganglioside storage in affected neural tissue.
    evidence:
    - reference: PMID:22025593
      reference_title: "Natural history of infantile G(M2) gangliosidosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
      explanation: Natural-history data link beta-hexosaminidase deficiency to ganglioside accumulation in the brain.
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
    explanation: Supports elevated GM2/ganglioside storage in affected brain tissue.
genetic:
- name: HEXA
  gene_term:
    preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  variants:
  - name: HEXA p.Gly269Ser (G269S)
    description: >
      Recurrent late-onset Tay-Sachs allele associated with residual
      beta-hexosaminidase A activity, delayed onset, and slower progression in
      homozygosity.
    clinical_significance: PATHOGENIC
    type: missense
    evidence:
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Disease onset (age 36 years) was delayed and progression relatively slower in the homozygous G269S patient."
      explanation: Cohort data support G269S as a pathogenic residual-activity allele with a later and slower phenotype.
  evidence:
  - reference: PMID:40710901
    reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
    explanation: Review supports HEXA as the causative gene for Tay-Sachs disease.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients' alpha-subunit mutations (beta-Hexosaminidase A genotype) were determined and correlated with their corresponding clinical findings and disease course."
    explanation: Late-onset cohort links HEXA alpha-subunit genotypes to clinical disease course.
  - reference: CGGV:assertion_1f7530b5-af31-40f9-ac18-a1b4d404285a-2020-05-27T160000.000Z
    reference_title: "HEXA / Tay-Sachs disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HEXA | HGNC:4878 | Tay-Sachs disease | MONDO:0010100 | AR | Definitive"
    explanation: ClinGen classifies the HEXA-Tay-Sachs disease gene-disease relationship as definitive with autosomal recessive inheritance.
  notes: Autosomal recessive, higher frequency in Ashkenazi Jewish population
treatments:
- name: Hematopoietic stem cell transplantation (HSCT)
  description: >-
    HSCT has been investigated as a means of restoring HexA enzyme activity
    in Tay-Sachs disease. An 8-year longitudinal case in late-onset Tay-Sachs
    documented normalized HexA enzyme activity and arrested neurodegenerative
    progression following allogeneic HSCT — the first compelling human
    evidence that enzyme restoration can halt disease progression. HSCT is
    not standard of care, has substantial procedure-related risk, and shows
    limited CNS penetrance, but remains an active area of investigation.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
  evidence:
  - reference: PMID:29214523
    reference_title: "Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HSCT is a potential treatment option which might arrest neurodegeneration in patients with LOTS."
    explanation: >-
      8-year longitudinal HSCT case in late-onset Tay-Sachs disease with
      HexA enzyme normalization and arrested neurodegeneration — first
      compelling human evidence that enzyme restoration halts disease
      progression.
- name: Supportive Care
  description: Symptomatic management including seizure control, nutrition support, respiratory care.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:27491214
    reference_title: "The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy."
    supports: SUPPORT
    snippet: "Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."
    explanation: Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.
- name: Genetic Counseling
  description: Carrier screening especially in high-risk populations.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:12108829
    reference_title: "Tay-Sachs disease screening and counseling families at risk for metabolic disease."
    supports: SUPPORT
    snippet: "Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."
    explanation: Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.
- name: Substrate Reduction Therapy
  description: Investigational approaches to reduce GM2 synthesis using glucose analogs such as miglustat to limit substrate flux into the ganglioside pathway.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  review_notes: Needs a more specific MAXO term for substrate reduction therapy.
  evidence:
  - reference: PMID:27491214
    reference_title: "The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy."
    supports: SUPPORT
    snippet: "Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients."
    explanation: Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses.
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There are also clinical reports of substrate reduction therapy using miglustat and bone marrow or hematopoietic stem cell transplantation."
    explanation: Review documents miglustat-based substrate reduction therapy as an investigational/off-label option in Tay-Sachs disease.
- name: Pharmacological Chaperone Therapy
  description: Investigational pharmacological chaperones (e.g., pyrimethamine) aim to stabilize residual mutant HEXA folding and trafficking and increase residual hexosaminidase A activity, particularly in mutation-dependent late-onset disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyrimethamine
      term:
        id: CHEBI:8673
        label: pyrimethamine
  review_notes: A more specific MAXO term for pharmacological chaperone therapy would be preferred when available.
  evidence:
  - reference: PMID:35865957
    reference_title: "Therapeutic Strategies For Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This review summarizes multiple drug development strategies for TSD, including enzyme replacement therapy, pharmaceutical chaperone therapy, substrate reduction therapy, gene therapy, and hematopoietic stem cell replacement therapy."
    explanation: Review of Tay-Sachs therapeutics establishes pharmaceutical chaperone therapy as one of the active drug-development strategies for the disease.
- name: Gene Therapy
  description: Experimental AAV-based gene therapy in clinical trials.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: PMID:35145305
    reference_title: "AAV gene therapy for Tay-Sachs disease."
    supports: SUPPORT
    snippet: "This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy."
    explanation: First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment.
clinical_trials:
- name: NCT04798235
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase 1/2 open-label study evaluating intrathecal TSHA-101 AAV9 gene
    therapy carrying HEXA and HEXB for infantile-onset GM2 gangliosidosis;
    ClinicalTrials.gov currently lists the study as active, not recruiting.
  target_phenotypes:
  - preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  - preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT04798235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary purpose of the current study is to assess the safety and tolerability of TSHA101 administered via IT injection."
    explanation: ClinicalTrials.gov record supports TSHA-101 as an intrathecal gene-therapy trial for infantile-onset GM2 gangliosidosis.
  notes: >-
    ClinicalTrials.gov lists this as a combined phase 1 and phase 2 study; the
    schema entry uses PHASE_I because the study begins with safety and
    tolerability assessment.
- name: NCT04669535
  phase: PHASE_I
  status: TERMINATED
  description: >-
    Open-label AXO-GM2-001 dose-escalation and safety/efficacy study of
    bilateral thalamic and intracisternal/intrathecal AXO-AAV-GM2 gene therapy
    in pediatric Tay-Sachs or Sandhoff disease; ClinicalTrials.gov currently
    lists the study as terminated.
  target_phenotypes:
  - preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  - preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT04669535
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AXO-AAV-GM2 is an investigational gene therapy that aims to restore HexA function by introducing a functional copy of the HEXA and HEXB genes via co-administration of two vectors utilizing the neurotropic adeno-associated virus recombinant human 8 serotype (AAVrh.8) capsid carrying the human HEXA or HEXB cDNA."
    explanation: ClinicalTrials.gov record supports AXO-AAV-GM2 as a dual-vector HEXA/HEXB gene-therapy trial relevant to Tay-Sachs disease.
datasets:
references:
- reference: PMID:20301397
  title: "HEXA Disorders."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:20301397

HEXA Disorders.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Tay–Sachs Disease (HEXA-related GM2 gangliosidosis variant B): Disease Characteristics Research Report

Edison Scientific Literature 47 citations 2026-04-25T22:35:19.387623

Tay–Sachs Disease (HEXA-related GM2 gangliosidosis variant B): Disease Characteristics Research Report

Target Disease

Disease name: Tay–Sachs disease (TSD) (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
Category: Genetic; lysosomal storage disorder (GM2 gangliosidosis) (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)

1. Disease information

Concise overview (current understanding)

Tay–Sachs disease is an autosomal recessive GM2 gangliosidosis caused by deficiency of lysosomal β-hexosaminidase A (HexA), leading to progressive GM2 ganglioside accumulation in neurons and neurodegeneration (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2). Tay–Sachs is classically subdivided into infantile, juvenile, and late-/adult-onset clinical forms that correlate with residual HexA activity (gonzalezsanchez2025advancesindiagnosis pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4).

Direct abstract quotes (examples) - From a fetal-brain transcriptomics study (Feb 2023): the authors state they identified “dramatic changes in the transcriptome, suggesting a perturbation of normal development” and that fetal transcriptomes were “perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment” (han2023geneexpressionchanges pages 1-3).

Key identifiers, synonyms, and alternative names

Identifier system	ID/code	Preferred label	Notes/source
OMIM (disease)	272800	Tay–Sachs disease	Retrieved review explicitly lists OMIM 272800 for TSD; described as a rare autosomal recessive GM2 gangliosidosis caused by HEXA-related HexA deficiency (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
OMIM (gene)	606869	HEXA	Retrieved primary study gives HEXA (MIM# 606869) as the causal gene encoding the alpha subunit of β-hexosaminidase A (ibrahim2023biochemicalandmutational pages 1-2)
Orphanet	ORPHA:845	Tay–Sachs disease	Retrieved review explicitly lists ORPHANET/Orphanet ORPHA845 for TSD (gonzalezsanchez2025advancesindiagnosis pages 1-2)
MeSH	not found in retrieved sources	Tay–Sachs disease	MeSH identifier was not present in the retrieved evidence set used here; disease overview and synonyms supported by retrieved literature (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
ICD-10	not found in retrieved sources	Tay–Sachs disease	ICD-10 code not present in the retrieved evidence set used here (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
ICD-11	not found in retrieved sources	Tay–Sachs disease	ICD-11 code not present in the retrieved evidence set used here (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
MONDO	not found in retrieved sources	Tay–Sachs disease	MONDO identifier was not present in the retrieved evidence set used here (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
Disease class / classification	GM2 gangliosidosis variant B	Tay–Sachs disease	Retrieved sources state TSD is also known as GM2 gangliosidosis variant B and belongs to the GM2 gangliosidoses; inheritance is autosomal recessive (ibrahim2023biochemicalandmutational pages 1-2, picache2022therapeuticstrategiesfor pages 1-2)
Synonym	—	Tay–Sachs disease	Common preferred disease name in all retrieved sources (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2, picache2022therapeuticstrategiesfor pages 1-2)
Synonym	—	GM2 gangliosidosis variant B	Explicit synonym in retrieved primary literature (ibrahim2023biochemicalandmutational pages 1-2)
Synonym	—	Hexosaminidase A deficiency	Functional disease descriptor supported by retrieved sources describing HexA deficiency as the defining biochemical defect (gonzalezsanchez2025advancesindiagnosis pages 1-2, picache2022therapeuticstrategiesfor pages 1-2)

Table: This table summarizes key retrieved identifiers and synonyms for Tay–Sachs disease, including disease and gene OMIM entries, Orphanet ID, classification, and supported alternative names. It also flags identifier systems not found in the retrieved evidence so the final report can clearly distinguish confirmed versus missing mappings.

Synonyms/related labels used in the literature: GM2 gangliosidosis variant B; hexosaminidase A deficiency (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 1-2).
MONDO ID: not found in the retrieved evidence set used for this report (artifact-00).

Evidence provenance

Most content here is derived from aggregated disease-level resources/reviews plus primary cohort studies and clinical trial registry records. Examples include a 2023 infantile Tay–Sachs cohort study in Egypt (Orphanet Journal of Rare Diseases) (ibrahim2023biochemicalandmutational pages 1-2), fetal brain transcriptomics (Journal of Inherited Metabolic Disease) (han2023geneexpressionchanges pages 1-3), and ClinicalTrials.gov records (NCT04798235 chunk 1).

2. Etiology

Disease causal factors

Primary cause: biallelic pathogenic variants in HEXA (OMIM 606869) resulting in deficient HexA enzyme activity and lysosomal GM2 accumulation (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 5-7).
Tay–Sachs is one of the GM2 gangliosidoses, which also include Sandhoff disease (HEXB) and AB-variant disease (GM2A) (gonzalezsanchez2025advancesindiagnosis pages 7-9, ashiri2023usinganengineered pages 16-23).

Risk factors

Genetic risk: carrier status for pathogenic HEXA variants; risk is elevated in some founder populations. A 2023 cohort paper summarizes carrier frequency being substantially higher in Ashkenazi Jewish populations (reported ~1/25) compared with ~1/250–300 in many other populations (ibrahim2023biochemicalandmutational pages 1-2).
Consanguinity: in a 2023 Egyptian infantile cohort, most affected children were born to consanguineous marriages (10/13) (ibrahim2023biochemicalandmutational pages 1-2).

Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence set. A biologic “protective” concept is that higher residual HexA activity is associated with later onset and milder disease (i.e., acts as a functional modifier), but this is not a protective variant per se (gonzalezsanchez2025advancesindiagnosis pages 2-4).

Gene–environment interactions

No specific gene–environment interactions were identified in the retrieved evidence set; Tay–Sachs is best characterized as a monogenic disorder with phenotype strongly related to enzyme activity and variant class (gonzalezsanchez2025advancesindiagnosis pages 2-4).

3. Phenotypes

Phenotype spectrum and HPO mapping

Subtype (with typical onset)	Key clinical features (plain language)	Suggested HPO terms (IDs and labels)	Natural history/progression (including survival estimates)	Frequency data (if available)	Key sources
Infantile Tay–Sachs disease (typically 3–6 months)	Initially normal infant, then irritability, mild motor weakness, exaggerated startle/hyperacusis, inability to sit, developmental regression, cherry-red macular spot, visual loss/blindness, feeding difficulty/dysphagia, seizures, later spasticity, dyskinesia, macrocephaly, cognitive decline, vegetative state	HP:0001257 Spasticity; HP:0002376 Developmental regression; HP:0001344 Hyperreflexia; HP:0002072 Chorea/dyskinesia-related abnormal involuntary movements; HP:0001250 Seizure; HP:0000518 Cataract not appropriate / use HP:0010729 Cherry red spot of the macula; HP:0000407 Sensorineural hearing impairment / hyperacusis feature not directly matched here; HP:0002015 Dysphagia; HP:0000256 Macrocephaly; HP:0001252 Hypotonia	Progressive neurodegeneration begins in the first year; cherry-red spot is typically present by ~6 months; vision loss develops by 12–18 months and many patients are blind by ~30 months; rapid worsening between ~8–10 months; tonic–myoclonic seizures often by ~12 months; later refractory seizures, dysphagia, decerebrate posturing, vegetative state; death usually at 2–5 years despite supportive care	“More than two-thirds” require multiple anticonvulsants for seizure control; in one Egyptian cohort all 13/13 biochemically confirmed cases had infantile disease; Ashkenazi carrier frequency reported ~1/25 vs ~1/250–300 in many other populations	(gonzalezsanchez2025advancesindiagnosis pages 9-11, ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Juvenile / subacute Tay–Sachs disease (typically 2–10 years; some sources 3–5 years)	Speech difficulty, clumsiness, gait problems, limb weakness, progressive spasticity, seizures, optic atrophy/vision decline; often more variable than infantile disease and may lack an early cherry-red spot	HP:0002463 Speech impairment; HP:0002317 Unsteady gait; HP:0003324 Muscle weakness; HP:0001257 Spasticity; HP:0001250 Seizure; HP:0000648 Optic atrophy; HP:0002376 Developmental regression	Intermediate course between infantile and adult forms; gradual neurologic deterioration over years with loss of motor function and increasing dependency; death commonly in adolescence or by mid-adolescence	Specific phenotype frequencies were not provided in the retrieved juvenile-focused excerpts; review data cited elsewhere note limb weakness and ataxic gait as common, but no robust juvenile percentage table was available in retrieved primary evidence	(gonzalezsanchez2025advancesindiagnosis pages 2-4, ibrahim2023biochemicalandmutational pages 1-2, sheth2018identificationofdeletionduplication pages 1-2)
Late-onset / adult Tay–Sachs disease (adolescence to adulthood; often 20s–30s)	Slowly progressive muscle weakness, clumsy or ataxic gait, tremor, dysarthria/stuttering or other distinct speech changes, falls, difficulty climbing stairs, fatigue, cerebellar signs, triceps/quadriceps wasting, psychiatric symptoms including psychosis/delusions/impulsivity, mild cognitive or subcortical deficits	HP:0001324 Muscle weakness; HP:0002066 Gait ataxia; HP:0001337 Tremor; HP:0001260 Dysarthria; HP:0002521 Cerebellar atrophy; HP:0007018 Falls; HP:0012378 Fatigue; HP:0000709 Psychosis; HP:0000738 Hallucinations/delusions-related psychiatric disturbance; HP:0002354 Memory impairment	Chronic, slowly progressive course with prolonged survival; diagnostic delay is common; patients may first present to neuromuscular, movement-disorder, or psychiatric services; loss of ambulation may occur later and lifespan is variable	Patient/caregiver burden study: muscle weakness 19/20 (95%), difficulty walking 19/20 (95%), falling 17/20 (85%), climbing stairs 16/20 (80%), “clumsy” gait 12/20 (60%), fatigue 10/20 (50%), coughing fits 5/20 (25%), GI issues 4/20 (20%); psychiatric symptoms may be the initial manifestation in up to half of patients	(lyn2020patientandcaregiver pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 4-5, barritt2017lateonsettay–sachsdisease pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4)

Table: This table summarizes Tay–Sachs disease manifestations across infantile, juvenile, and late-onset forms, linking clinical features to suggested HPO terms, natural history, and available frequency data. It is useful for phenotype curation, diagnostic support, and subtype-specific knowledge base entry development.

Quality-of-life impact (late-onset disease)

A qualitative study of late-onset GM2 gangliosidosis (including late-onset Tay–Sachs) quantified commonly reported symptoms and functional impacts. Frequently reported items included muscle weakness (95%), difficulty walking (95%), falling (85%), and difficulty climbing stairs (80%), emphasizing substantial impairment of mobility/independence and downstream psychosocial burden (lyn2020patientandcaregiver pages 1-2).

4. Genetic / molecular information

Causal gene(s)

HEXA is the causal gene for Tay–Sachs disease; HEXA encodes the α-subunit of HexA (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 7-9).

Pathogenic variants (examples and variant types)

A 2023 infantile cohort study (Egypt; publication date Mar 2023; URL https://doi.org/10.1186/s13023-023-02637-1) reported multiple novel likely pathogenic variants and recurrent exon 13 variants, including missense and frameshift changes; mean HexA activity in affected children was severely reduced (ibrahim2023biochemicalandmutational pages 1-2).
Exon-level deletions/duplications can cause disease and may be missed by exon sequencing alone; MLPA identified exon 1 deletions/duplications and exon 2–3 deletions in enzymatically confirmed cases (sheth2018identificationofdeletionduplication pages 2-3, sheth2018identificationofdeletionduplication pages 1-2).
Late-onset presentations can involve combinations such as frameshift plus the common late-onset variant c.805G>A (p.Gly269Ser) in HEXA (barritt2017lateonsettay–sachsdisease pages 1-2).

Functional consequences

Pathogenic HEXA variants generally produce loss of function by disrupting protein folding, heterodimer assembly, lysosomal trafficking, or catalytic function, ultimately preventing HexA-mediated hydrolysis of GM2 (ashiri2023usinganengineered pages 23-28, gonzalezsanchez2025advancesindiagnosis pages 7-9).

Modifier genes / epigenetics / chromosomal abnormalities

No robust modifier genes, epigenetic drivers, or chromosomal abnormalities specific to Tay–Sachs were identified in the retrieved evidence set.

5. Environmental information

Tay–Sachs is not established as an environmentally triggered disorder; no non-genetic causal environmental factors were identified in the retrieved evidence set.

6. Mechanism / pathophysiology

Core biochemical defect and causal chain

HEXA loss-of-function causes deficient lysosomal HexA activity (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 7-9).
HexA “specifically hydrolyzes the N-acetylgalactosamine residue in GM2 ganglioside,” and deficiency leads to “accumulation of GM2 gangliosides within lysosomes” (gonzalezsanchez2025advancesindiagnosis pages 7-9).
GM2 accumulation contributes to lysosomal dysfunction (including lysosomal disruption) and neurodegeneration, with neuronal loss and gliosis (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 5-7).
Downstream mechanisms include ER stress and apoptosis (neuron death) as well as neuroinflammation characterized by microglial activation and astrogliosis (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 9-11).

Neuroinflammation and glial involvement

A 2025 review states “astrogliosis has been identified as a critical component of GM2 gangliosidosis pathophysiology” and highlights that “astrocyte-microglia crosstalk is essential for amplifying neuroinflammatory responses” (gonzalezsanchez2025advancesindiagnosis pages 9-11). Candidate CSF inflammatory biomarkers for infantile disease include ENA-78, MCP-1, MIP-1α, MIP-1β, and TNFR2 (gonzalezsanchez2025advancesindiagnosis pages 9-11).

Myelin/oligodendrocyte involvement and biomarker data (large animal model)

In a sheep natural-history model (publication date Sep 2021; URL https://doi.org/10.1016/j.ymgme.2021.08.009), disease severity tracked with CSF GM2, MRI/MRS markers, and neuropathology including early oligodendrocyte loss and demyelination signatures (story2021naturalhistoryof pages 5-7). Reported MRS patterns included increased myoinositol (gliosis), increased taurine, increased choline-related markers (demyelination), and decreased NAA (neuronal/axonal integrity) (story2021naturalhistoryof pages 5-7).

Developmental stage mechanisms (human fetal brain)

A 2023 RNA-seq study of human fetal Tay–Sachs brain found transcriptomes “perturbed by 17 week’s gestation” and a “shift in the expression of the sphingolipid metabolic pathway away from production of the HEXA substrate, GM2 ganglioside,” implying compensatory remodeling and that developmental perturbations may precede overt neurodegeneration (han2023geneexpressionchanges pages 1-3).

Suggested ontology terms

GO (biological process) suggestions: ganglioside catabolic process; sphingolipid metabolic process; lysosomal organization; response to endoplasmic reticulum stress; apoptotic process; microglial activation; astrocyte activation; neuroinflammatory response; myelination (supported conceptually by mechanistic and pathology evidence) (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 9-11, story2021naturalhistoryof pages 5-7).
CL (cell type) suggestions: microglia; astrocyte; oligodendrocyte; radial glial cell; neuron (including cerebellar Purkinje neuron) (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 9-11, story2021naturalhistoryof pages 5-7).

7. Anatomical structures affected

Organ/system level

Primary system: central nervous system (progressive neurodegeneration) (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 2-4).
Neuroanatomical involvement noted on imaging/pathology includes thalamus and cerebral atrophy patterns in clinical descriptions and animal models (gonzalezsanchez2025advancesindiagnosis pages 5-7, story2021naturalhistoryof pages 5-7).

Tissue/cell level

Neuronal lysosomal storage with gliosis (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 9-11).
Oligodendrocyte/myelin abnormalities suggested by sheep natural history (story2021naturalhistoryof pages 5-7).

Subcellular level

Lysosome is the key compartment for substrate accumulation (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 7-9).

Suggested anatomical ontology terms

UBERON suggestions: brain; thalamus; cerebellum; cerebral cortex; white matter; spinal cord (supported by sampling sites and pathology descriptions across sources) (story2021naturalhistoryof pages 5-7, han2023geneexpressionchanges pages 1-3).

8. Temporal development

Infantile onset: typically 3–6 months with early sensory hypersensitivity/startle, regression, and rapid progression; seizures often develop by ~12 months in one synthesis (gonzalezsanchez2025advancesindiagnosis pages 9-11).
Progression: infantile disease progresses to severe disability, vegetative state, and death commonly in early childhood (2–5 years across sources) (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4).
Late-onset: chronic progression across years with variable lifespan and often long diagnostic delays; psychiatric symptoms may be initial in up to half of patients in one review (gonzalezsanchez2025advancesindiagnosis pages 4-5).

9. Inheritance and population

Inheritance pattern: autosomal recessive (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2).
Epidemiology (illustrative figures from recent secondary sources): One review reports ~1 in 100,000 live births in the U.S. and carrier frequency ~1 in 250, with much higher incidence in Ashkenazi Jewish populations (~1 in 3,900 without screening; carrier ~1 in 29 in some studies) (gonzalezsanchez2025advancesindiagnosis pages 2-4). A 2023 cohort paper summarizes higher carrier frequency in Ashkenazi Jewish populations (~1 in 25) versus ~1/250–300 in many other populations (ibrahim2023biochemicalandmutational pages 1-2).

10. Diagnostics

Test/approach	Specimen	What it measures	Interpretation pitfalls	Typical use case (diagnosis/carrier/prenatal)	Notes	Key sources
HexA/HexB enzyme activity assay using artificial substrates (e.g., MUG/MUGS with thermal differentiation)	Leukocytes, serum, cultured skin fibroblasts, chorionic villi, dried blood spots, other cells/tissues/biological fluids	Total hexosaminidase and HexA-specific activity; confirms biochemical deficiency	Pseudodeficiency alleles can lower in vitro activity on synthetic substrates without causing disease; carrier detection by enzyme assay alone can be unreliable	Primary diagnosis; confirmatory testing; prenatal when performed on fetal material	Gold-standard confirmatory specimens in retrieved sources are fibroblasts, chorionic villi, or leukocytes; infantile disease often shows very low/absent activity, juvenile higher residual activity (gonzalezsanchez2025advancesindiagnosis pages 4-5, ashiri2023usinganengineered pages 23-28, gonzalezsanchez2025advancesindiagnosis pages 2-4)	(gonzalezsanchez2025advancesindiagnosis pages 4-5, ashiri2023usinganengineered pages 23-28, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Dried blood spot (DBS) HexA assay	Dried blood spots	Screening/initial biochemical detection of low HexA activity	Positive/abnormal DBS requires confirmatory enzyme and molecular testing; not sufficient alone for definitive molecular characterization	Early diagnosis; newborn/remote screening workflows; triage to confirmatory testing	Reported as practical standard-of-care style primary test in one study; can be paired with sequencing/WES follow-up (bibi2021taysachsdiseasetwo pages 5-8, gonzalezsanchez2025advancesindiagnosis pages 2-4)	(bibi2021taysachsdiseasetwo pages 5-8, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Targeted HEXA variant analysis / common-variant panels	Blood or genomic DNA	Detects recurrent pathogenic alleles and selected adult-onset/pseudodeficiency alleles	Limited if patient carries rare/private variants or CNVs; founder-focused panels may miss non-founder mutations	Carrier screening; targeted diagnostic follow-up in high-risk populations	Retrieved review notes panels including common null alleles plus adult-onset p.Gly269Ser and pseudodeficiency alleles p.Arg247Trp / p.Arg249Trp (gonzalezsanchez2025advancesindiagnosis pages 4-5)	(gonzalezsanchez2025advancesindiagnosis pages 4-5)
Sanger sequencing of HEXA coding exons and splice junctions	Genomic DNA from blood	Single-nucleotide variants and small indels in coding/splice regions	Can miss deep intronic/regulatory variants and exon-level deletions/duplications; partial detection only in some cohorts	Diagnostic confirmation after low enzyme activity; family testing	In the Egyptian infantile cohort, bidirectional Sanger sequencing had ~62% detection (8/13), prompting recommendation for broader NGS/CNV-aware workup when unresolved (ibrahim2023biochemicalandmutational pages 1-2)	(ibrahim2023biochemicalandmutational pages 1-2)
Next-generation sequencing (targeted panels/WES; CNV-aware if possible)	Genomic DNA	Broad detection of HEXA variants, including rare/private pathogenic variants; may support broader differential diagnosis	Requires variant interpretation; may still miss some structural/regulatory defects if CNV calling is inadequate	Diagnosis of unresolved cases; family studies; carrier workup in diverse populations	Recommended when Sanger is negative or only one pathogenic allele is found; WES identified novel homozygous HEXA variants in Pakistani/Moroccan families (bibi2021taysachsdiseasetwo pages 5-8, ibrahim2023biochemicalandmutational pages 1-2)	(bibi2021taysachsdiseasetwo pages 5-8, ibrahim2023biochemicalandmutational pages 1-2)
MLPA (deletion/duplication analysis)	Genomic DNA from whole blood	Exon-level copy-number changes in HEXA	Not designed for SNVs/small indels; usually used after sequencing fails to identify both alleles	Diagnostic resolution of sequencing-inconclusive cases; family studies	Detected homozygous exon 2-3 deletions, exon 1 deletions with a missense variant, and exon 1 duplication with splice variant; specifically recommended when one/both alleles are missing by sequencing (sheth2018identificationofdeletionduplication pages 2-3, sheth2018identificationofdeletionduplication pages 1-2)	(sheth2018identificationofdeletionduplication pages 2-3, sheth2018identificationofdeletionduplication pages 1-2)
Prenatal enzyme testing on chorionic villi / chorionic villus sampling (CVS)	Chorionic villi (typically 10-12 weeks)	Fetal HexA activity and/or fetal genotype	Requires correct parental interpretation and awareness of pseudodeficiency alleles; invasive procedure	Prenatal diagnosis in at-risk pregnancies	Retrieved review explicitly identifies CVS as a prenatal option and chorionic villi as a gold-standard specimen type for enzyme testing (gonzalezsanchez2025advancesindiagnosis pages 4-5, gonzalezsanchez2025advancesindiagnosis pages 2-4)	(gonzalezsanchez2025advancesindiagnosis pages 4-5, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Prenatal testing by amniocentesis	Amniotic fluid/fetal cells (typically 15-18 weeks)	Fetal genotype and/or biochemical testing depending laboratory workflow	Same interpretive issues as other prenatal tests; invasive procedure	Prenatal diagnosis in at-risk pregnancies	Retrieved review gives amniocentesis at 15-18 weeks as an option when parental carrier status/risk is established (gonzalezsanchez2025advancesindiagnosis pages 4-5)	(gonzalezsanchez2025advancesindiagnosis pages 4-5)
Carrier screening programs (premarital/preconception/community screening)	Blood/DBS/DNA depending program	Identifies heterozygous carriers to inform reproductive risk	Enzyme-based carrier screening can be confounded by pseudodeficiency; molecular confirmation improves specificity	Carrier screening; public health prevention	In Ashkenazi Jewish communities, premarital carrier screening was associated with an approximately 95% reduction in Tay-Sachs incidence in retrieved evidence; historical founder frequencies are much higher than general-population rates (gonzalezsanchez2025advancesindiagnosis pages 2-4, ashiri2023usinganengineered pages 23-28)	(gonzalezsanchez2025advancesindiagnosis pages 2-4, ashiri2023usinganengineered pages 23-28)
Integrated diagnostic workflow	Start with leukocytes/fibroblasts/DBS, then DNA-based testing	Combines biochemical confirmation with molecular definition of genotype	Overreliance on a single modality can miss carriers, pseudodeficiency, or CNVs	Best-practice diagnostic pathway	Practical pathway from retrieved evidence: low HexA activity -> sequencing -> del/dup analysis/NGS if unresolved; use prenatal testing when familial pathogenic variants are known (gonzalezsanchez2025advancesindiagnosis pages 4-5, ibrahim2023biochemicalandmutational pages 1-2, sheth2018identificationofdeletionduplication pages 2-3)	(gonzalezsanchez2025advancesindiagnosis pages 4-5, ibrahim2023biochemicalandmutational pages 1-2, sheth2018identificationofdeletionduplication pages 2-3)

Table: This table summarizes the main diagnostic and screening approaches for Tay-Sachs disease, including biochemical, molecular, prenatal, and carrier-screening methods. It highlights specimen types, what each test measures, common pitfalls such as pseudodeficiency alleles, and how these methods are used in real-world diagnostic pathways.

Real-world diagnostic implementation notes

A practical approach in the retrieved evidence is biochemical confirmation (HexA activity) followed by genotyping and, if needed, del/dup analysis such as MLPA to detect exon-level CNVs (gonzalezsanchez2025advancesindiagnosis pages 4-5, sheth2018identificationofdeletionduplication pages 2-3).
The first-in-human gene therapy case report highlights the clinical necessity for confirmed diagnosis and the use of CSF HexA activity as a pharmacodynamic readout in treated infants (flotte2022aavgenetherapy pages 1-6).

11. Outcome / prognosis

Infantile Tay–Sachs: poor prognosis with death typically in early childhood despite supportive care; one review summarizes death usually by ~5 years (gonzalezsanchez2025advancesindiagnosis pages 2-4), and a 2023 cohort paper describes death at ~2–4 years for the classical infantile phenotype (ibrahim2023biochemicalandmutational pages 1-2).
Seizure burden: one synthesis states “more than two-thirds” require multiple anticonvulsants for seizure control (gonzalezsanchez2025advancesindiagnosis pages 9-11).
Late-onset disease: prolonged survival but high functional burden, with frequent falls and mobility limitations (lyn2020patientandcaregiver pages 1-2).

12. Treatment

Modality	Example intervention	Mechanism/rationale	Evidence level (human/animal/in vitro)	Key quantitative results	Status/real-world use	ClinicalTrials.gov IDs if applicable	Key sources
In vivo gene therapy	AAVrh8-HEXA + AAVrh8-HEXB (expanded-access; AXO-AAV-GM2 platform)	Dual-vector replacement of both HexA subunits to restore CNS HexA activity; delivered intrathecally and/or intrathalamically because broad CNS distribution is required	Human clinical + supporting animal studies	In 2 infantile TSD patients, CSF HexA activity “nearly doubled from baseline and remained stable”; no vector-related AEs reported; one patient treated at 7 months showed MRI stabilization at 3 months but decline by 6 months; one older patient remained seizure-free at 4.5–5 years on same anticonvulsant regimen. Doses included 1×10^14 vg IT (75% cisterna magna, 25% thoracolumbar) and 4.2×10^13 vg combined thalamic+IT (flotte2022aavgenetherapy pages 1-6)	First-in-human proof-of-concept; not approved	Expanded access under IND 18225; follow-up study NCT06614569	(flotte2022aavgenetherapy pages 1-6, gonzalezsanchez2025advancesindiagnosis pages 15-17)
Interventional clinical trial, gene therapy	AXO-AAV-GM2 dose-escalation study	Same dual-AAV gene replacement strategy for infantile GM2 gangliosidosis/Tay-Sachs or Sandhoff disease	Human clinical trial	Phase 1; enrollment 9; trial status reported as TERMINATED in retrieved registry results (no efficacy outcomes in retrieved context)	Clinical development program; not approved	NCT04669535	(NCT04798235 chunk 1)
Interventional clinical trial, gene therapy	TSHA-101 (AAV9 carrying HEXA and HEXB)	One-time intrathecal AAV9 delivery of HEXA+HEXB to address HexA deficiency in infantile GM2 gangliosidosis	Human clinical trial	Active not recruiting; actual enrollment 3; outcomes include CSF/serum HexA activity, CHOP-INTEND, overall survival up to 5 years; quantitative efficacy not yet available in retrieved context	Ongoing early-phase clinical development; not approved	NCT04798235	(NCT04798235 chunk 1)
Substrate reduction therapy	Miglustat	Inhibits glycosphingolipid synthesis upstream to reduce GM2 substrate burden	Animal + human clinical	In mouse models, reduced brain GM2 by up to 50% and prolonged survival; in a 24-month study of 5 juvenile patients, did not halt neurological deterioration (gonzalezsanchez2025advancesindiagnosis pages 14-15)	Off-label/experimental in GM2; not FDA-approved for Tay-Sachs	NCT00418847; NCT00672022; NCT03822013	(gonzalezsanchez2025advancesindiagnosis pages 14-15, abidi2024metabolismofglycosphingolipids pages 85-90)
Next-generation substrate reduction therapy	Nizubaglustat (AZ-3102)	Small-molecule substrate reduction approach for GM2 gangliosidosis/NPC disease	Human clinical trial	Phase 2 recruiting; planned enrollment 21; no efficacy results yet in retrieved context	Investigational	NCT07399704	(NCT04798235 chunk 1)
Pharmacological chaperone	Pyrimethamine	Mutation-dependent stabilization/folding rescue of residual HexA, with BBB penetration	In vitro + human clinical experience summarized in reviews	Induced up to a threefold increase in enzymatic activity in TSD fibroblasts, but neurological benefit in patients has been limited/mutation-dependent (gonzalezsanchez2025advancesindiagnosis pages 14-15)	Experimental/off-label; not standard disease-modifying therapy	not provided in retrieved context	(gonzalezsanchez2025advancesindiagnosis pages 14-15, ou2020anovelgene pages 11-11)
Enzyme replacement therapy	Engineered human HexA / rhHexA	Supplies exogenous enzyme to degrade stored GM2; major challenge is BBB/CNS delivery	Animal + in vitro	Engineered HexA degraded GM2 in Hexa-/- mouse-related systems and prevented severe storage in preclinical work; yeast-produced rhHexA reduced lysosomal mass and GM2 levels in patient fibroblasts/neuroglial cells after 72 h treatment (ashiri2023usinganengineered pages 23-28, abidi2024metabolismofglycosphingolipids pages 85-90)	Preclinical; no approved ERT for Tay-Sachs	not applicable	(ashiri2023usinganengineered pages 23-28, abidi2024metabolismofglycosphingolipids pages 85-90, picache2022therapeuticstrategiesfor pages 1-2)
Recombinant enzyme production / cell studies	Yeast-produced human recombinant lysosomal β-hexosaminidase A (rhHex-A)	Scalable recombinant enzyme for cellular rescue of GM2 storage	In vitro	In patient and murine cell systems, 100 nM rhHexA for 72 h reduced lysosomal mass and GM2/LAMP1 colocalization; authors concluded rhHex-A “can efficiently degrade GM2 ganglioside and rescue lysosomal accumulation”	Preclinical research only	not applicable	(abidi2024metabolismofglycosphingolipids pages 85-90)
Protein delivery across BBB	Dual trojan horse HEXA protein (HEXA linked to BBB-entry motifs)	Enzyme delivery strategy to shuttle HEXA across BBB, associate with HEXB, reach lysosomes, and reduce brain GM2	Animal + in vitro	In adult LOTS-model mice, IV treatment reduced whole-brain GM2 by ~40% within 6 weeks and improved forelimb grip strength; also lowered GM2 in cultured human Tay-Sachs glial cells (osher2024treatinglateonsettay pages 1-2)	Preclinical; not approved	not applicable	(osher2024treatinglateonsettay pages 1-2)
Broad therapeutic category	HSCT / bone marrow transplantation	Cross-correction via donor-derived enzyme-producing cells	Human case series/reviewed clinical experience	Can increase systemic HexA; reported survival prolongation in some cases, but overall insufficient CNS correction and no consistent motor improvement (gonzalezsanchez2025advancesindiagnosis pages 14-15)	Not established as effective disease-modifying standard for Tay-Sachs CNS disease	not provided in retrieved context	(gonzalezsanchez2025advancesindiagnosis pages 14-15, gonzalezsanchez2025advancesindiagnosis pages 15-17)
Emerging pathway-targeted SRT	B4GALNT1 / GM2 synthesis inhibition (e.g., lead compound QT163)	Directly target GM2 synthesis pathway to reduce GM2 and lyso-GM2 production	Preclinical in vitro/drug discovery	Lead compound QT163 showed strongest inhibition with reported IC50 0.2 mM; lyso-GM2 proposed as biomarker for diagnosis/treatment monitoring (abidi2024metabolismofglycosphingolipids pages 85-90)	Experimental discovery-stage	not applicable	(abidi2024metabolismofglycosphingolipids pages 85-90)

Table: This table summarizes major therapeutic modalities and clinical-trial programs for Tay-Sachs/GM2 gangliosidosis, including current human gene-therapy studies, substrate-reduction approaches, pharmacological chaperones, and preclinical enzyme/protein-delivery strategies. It is useful for comparing mechanism, evidence maturity, quantitative outcomes, and current development status across the treatment landscape.

Key recent developments (prioritizing 2023–2024 sources)

2024 protein BBB-delivery strategy (late-onset model): a “dual trojan horse” HEXA protein lowered whole-brain GM2 by ~40% within 6 weeks in an adult Tay–Sachs mouse model and improved grip strength (publication date Sep 2024; URL https://doi.org/10.1016/j.omtm.2024.101300) (osher2024treatinglateonsettay pages 1-2).
2023 fetal-stage mechanistic insight: transcriptomic perturbations by 17 weeks’ gestation suggest a potentially earlier window for intervention than clinical onset (publication date Feb 2023; URL https://doi.org/10.1002/jimd.12596) (han2023geneexpressionchanges pages 1-3).

Human gene therapy evidence (first-in-human)

A first-in-human expanded-access experience (Nature Medicine version published Feb 2022; preprint posted Feb 18, 2021; URL https://doi.org/10.1038/s41591-021-01664-4; preprint URL https://doi.org/10.21203/rs.3.rs-195847/v1) reported intrathecal and intrathalamic delivery of AAVrh8-HEXA plus AAVrh8-HEXB in two infantile Tay–Sachs patients, with no vector-related adverse events and increased CSF HexA activity; MRI and seizure outcomes suggested partial/temporary deviation from expected infantile natural history in the younger-treated child (flotte2022aavgenetherapy pages 1-6).

Figure evidence: the treatment-associated HexA activity trajectories and delivery-route imaging are shown in retrieved figure/table regions from the case report (flotte2022aavgenetherapy media 379a08f6, flotte2022aavgenetherapy media 8b29bbe4, flotte2022aavgenetherapy media 4f87ceb4, flotte2022aavgenetherapy media c9927c10).

MAXO term suggestions (examples)

Gene therapy (intrathecal/intracerebral AAV delivery) (flotte2022aavgenetherapy pages 1-6, NCT04798235 chunk 1)
Enzyme replacement therapy / enzyme supplementation (preclinical) (gonzalezsanchez2025advancesindiagnosis pages 14-15)
Substrate reduction therapy (miglustat; investigational agents) (gonzalezsanchez2025advancesindiagnosis pages 14-15, NCT04798235 chunk 1)
Hematopoietic stem cell transplantation (selected contexts) (gonzalezsanchez2025advancesindiagnosis pages 14-15)

13. Prevention

Primary prevention via carrier screening: in some Ashkenazi communities, premarital carrier screening is associated with an approximately 95% reduction in incidence in a synthesis review (gonzalezsanchez2025advancesindiagnosis pages 2-4).
Secondary prevention / early detection: biochemical screening using dried blood spots and molecular confirmation can enable earlier diagnosis; prenatal diagnosis is feasible via CVS (10–12 weeks) or amniocentesis (15–18 weeks) in at-risk pregnancies (gonzalezsanchez2025advancesindiagnosis pages 4-5, bibi2021taysachsdiseasetwo pages 5-8).

14. Other species / natural disease

Naturally occurring large-animal model: Jacob sheep with a naturally occurring HEXA missense mutation develop progressive neurologic disease and GM2 accumulation; the model enables biomarker and therapeutic evaluation at a large-brain scale (story2021naturalhistoryof pages 1-2, story2021naturalhistoryof pages 5-7).
Additional natural disease has been described in other species (e.g., cats/dogs; wild boar variants mentioned in a compilation), but detailed comparative pathology was not comprehensively extractable from the retrieved evidence set (ashiri2023usinganengineered pages 129-133).

15. Model organisms

Mouse models: Hexa knockout mice show GM2 accumulation but may lack classical clinical phenotypes due to alternative GM2 catabolic pathways, limiting phenotypic fidelity for some questions (picache2022therapeuticstrategiesfor pages 6-8, gonzalezsanchez2025advancesindiagnosis pages 11-12).
Rabbit genome-edited model: prime editing of a common Tay–Sachs insertion produced late-onset–like neurologic and muscle pathology features (picache2022therapeuticstrategiesfor pages 6-8).
Sheep model (natural history): provides staged progression (mild symptoms at ~3 months; moderate at ~6 months; severe with humane endpoint around ~9 months), CSF GM2 biomarker utility, and MRI/MRS correlates (story2021naturalhistoryof pages 1-2, story2021naturalhistoryof pages 5-7).
Translational therapy testing: A 5-year AAV gene therapy analysis in Tay–Sachs sheep reported long survival after multipoint CSF delivery, supporting large-animal evaluation of delivery routes, biomarkers, and durability (publication date Sep 2025; URL https://doi.org/10.1172/jci182942) (taghian2025fiveyearanalysisof pages 1-2).

Limitations of this report (evidence availability)

ICD-10/ICD-11/MeSH/MONDO identifiers were not present in the retrieved evidence set and therefore are explicitly not populated to avoid hallucination (artifact-00).
Several key references in this area exist but were not retrievable within this tool run; consequently, some sections (e.g., global epidemiology by region, comprehensive variant frequency from gnomAD, formal clinical guidelines, and late-2024 Neurology Genetics diagnostic paper) could not be exhaustively covered.

References

(gonzalezsanchez2025advancesindiagnosis pages 1-2): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(ibrahim2023biochemicalandmutational pages 1-2): Doaa M. A. Ibrahim, Ola S. M. Ali, Hala Nasr, Ekram Fateen, and Alice AbdelAleem. Biochemical and mutational analyses of hexa in a cohort of egyptian patients with infantile tay-sachs disease. expansion of the mutation spectrum. Orphanet Journal of Rare Diseases, Mar 2023. URL: https://doi.org/10.1186/s13023-023-02637-1, doi:10.1186/s13023-023-02637-1. This article has 13 citations and is from a peer-reviewed journal.
(gonzalezsanchez2025advancesindiagnosis pages 2-4): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(han2023geneexpressionchanges pages 1-3): Sangwoo T. Han, Ashley Hirt, Elena‐Raluca Nicoli, Mari Kono, Camilo Toro, Richard L. Proia, and Cynthia J. Tifft. Gene expression changes in tay–sachs disease begin early in fetal brain development. Journal of Inherited Metabolic Disease, 46:687-694, Feb 2023. URL: https://doi.org/10.1002/jimd.12596, doi:10.1002/jimd.12596. This article has 10 citations and is from a peer-reviewed journal.
(picache2022therapeuticstrategiesfor pages 1-2): Jaqueline A. Picache, Wei Zheng, and Catherine Z. Chen. Therapeutic strategies for tay-sachs disease. Frontiers in Pharmacology, Jul 2022. URL: https://doi.org/10.3389/fphar.2022.906647, doi:10.3389/fphar.2022.906647. This article has 40 citations.
(NCT04798235 chunk 1): Dr. Anupam Sehgal. First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis. Dr. Anupam Sehgal. 2021. ClinicalTrials.gov Identifier: NCT04798235
(gonzalezsanchez2025advancesindiagnosis pages 5-7): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(gonzalezsanchez2025advancesindiagnosis pages 7-9): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(ashiri2023usinganengineered pages 16-23): M Ashiri. Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of tay-sachs disease. Unknown journal, 2023.
(gonzalezsanchez2025advancesindiagnosis pages 9-11): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(sheth2018identificationofdeletionduplication pages 1-2): Jayesh Sheth, Mehul Mistri, Lakshmi Mahadevan, Sanjeev Mehta, Dhaval Solanki, Mahesh Kamate, and Frenny Sheth. Identification of deletion-duplication in hexa gene in five children with tay-sachs disease from india. BMC Medical Genetics, Jul 2018. URL: https://doi.org/10.1186/s12881-018-0632-7, doi:10.1186/s12881-018-0632-7. This article has 11 citations and is from a peer-reviewed journal.
(lyn2020patientandcaregiver pages 1-2): Nicole Lyn, Ruth Pulikottil-Jacob, Camille Rochmann, Robert Krupnick, Chad Gwaltney, Nick Stephens, Julie Kissell, Gerald F. Cox, Tanya Fischer, and Alaa Hamed. Patient and caregiver perspectives on burden of disease manifestations in late-onset tay-sachs and sandhoff diseases. Orphanet Journal of Rare Diseases, Apr 2020. URL: https://doi.org/10.1186/s13023-020-01354-3, doi:10.1186/s13023-020-01354-3. This article has 19 citations and is from a peer-reviewed journal.
(gonzalezsanchez2025advancesindiagnosis pages 4-5): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(barritt2017lateonsettay–sachsdisease pages 1-2): Andrew W Barritt, Stuart J Anderson, P Nigel Leigh, and Basil H Ridha. Late-onset tay–sachs disease. Practical Neurology, 17:396-399, Jul 2017. URL: https://doi.org/10.1136/practneurol-2017-001665, doi:10.1136/practneurol-2017-001665. This article has 38 citations and is from a peer-reviewed journal.
(sheth2018identificationofdeletionduplication pages 2-3): Jayesh Sheth, Mehul Mistri, Lakshmi Mahadevan, Sanjeev Mehta, Dhaval Solanki, Mahesh Kamate, and Frenny Sheth. Identification of deletion-duplication in hexa gene in five children with tay-sachs disease from india. BMC Medical Genetics, Jul 2018. URL: https://doi.org/10.1186/s12881-018-0632-7, doi:10.1186/s12881-018-0632-7. This article has 11 citations and is from a peer-reviewed journal.
(ashiri2023usinganengineered pages 23-28): M Ashiri. Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of tay-sachs disease. Unknown journal, 2023.
(story2021naturalhistoryof pages 5-7): Brett Story, Toloo Taghian, Jillian Gallagher, Jey Koehler, Amanda Taylor, Ashley Randle, Kayly Nielsen, Amanda Gross, Annie Maguire, Sara Carl, Siauna Johnson, Deborah Fernau, Elise Diffie, Paul Cuddon, Carly Corado, Sundeep Chandra, Miguel Sena-Esteves, Edwin Kolodny, Xuntian Jiang, Douglas Martin, and Heather Gray-Edwards. Natural history of tay-sachs disease in sheep. Molecular Genetics and Metabolism, 134:164-174, Sep 2021. URL: https://doi.org/10.1016/j.ymgme.2021.08.009, doi:10.1016/j.ymgme.2021.08.009. This article has 13 citations and is from a peer-reviewed journal.
(bibi2021taysachsdiseasetwo pages 5-8): Farah Bibi, Asmat Ullah, Thomas Bourinaris, Stephanie Efthymiou, Yamna Kriouile, Tipu Sultan, Shahzad Haider, Vincenzo Salpietro, Henry Houlden, and Ghazala Kaukab Raja. Tay-sachs disease: two novel rare hexa mutations from pakistan and morocco. Klinische Pädiatrie, 233:226-230, Apr 2021. URL: https://doi.org/10.1055/a-1371-1561, doi:10.1055/a-1371-1561. This article has 17 citations.
(flotte2022aavgenetherapy pages 1-6): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.
(gonzalezsanchez2025advancesindiagnosis pages 15-17): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(gonzalezsanchez2025advancesindiagnosis pages 14-15): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(abidi2024metabolismofglycosphingolipids pages 85-90): I Abidi. Metabolism of glycosphingolipids and targeting gm2 synthesis pathway to develop substrate reduction approach in tay-sachs and sandhoff disorders. Unknown journal, 2024.
(ou2020anovelgene pages 11-11): Li Ou, Michael J. Przybilla, Alexandru-Flaviu Tăbăran, Paula Overn, M. Gerard O’Sullivan, Xuntian Jiang, Rohini Sidhu, Pamela J. Kell, Daniel S. Ory, and Chester B. Whitley. A novel gene editing system to treat both tay–sachs and sandhoff diseases. Gene Therapy, 27:226-236, Jan 2020. URL: https://doi.org/10.1038/s41434-019-0120-5, doi:10.1038/s41434-019-0120-5. This article has 70 citations and is from a peer-reviewed journal.
(osher2024treatinglateonsettay pages 1-2): Esther Osher, Yossi Anis, Ruth Singer-Shapiro, Nataly Urshanski, Tamar Unger, Shira Albeck, Oren Bogin, Gary Weisinger, Fortune Kohen, Avi Valevski, Aviva Fattal-Valevski, Liora Sagi, Michal Weitman, Yulia Shenberger, Nadav Sagiv, Ruth Navon, Meir Wilchek, and Naftali Stern. Treating late-onset tay sachs disease: brain delivery with a dual trojan horse protein. Molecular Therapy - Methods & Clinical Development, 32:101300, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101300, doi:10.1016/j.omtm.2024.101300. This article has 5 citations.
(flotte2022aavgenetherapy media 379a08f6): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.
(flotte2022aavgenetherapy media 8b29bbe4): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.
(flotte2022aavgenetherapy media 4f87ceb4): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.
(flotte2022aavgenetherapy media c9927c10): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.
(story2021naturalhistoryof pages 1-2): Brett Story, Toloo Taghian, Jillian Gallagher, Jey Koehler, Amanda Taylor, Ashley Randle, Kayly Nielsen, Amanda Gross, Annie Maguire, Sara Carl, Siauna Johnson, Deborah Fernau, Elise Diffie, Paul Cuddon, Carly Corado, Sundeep Chandra, Miguel Sena-Esteves, Edwin Kolodny, Xuntian Jiang, Douglas Martin, and Heather Gray-Edwards. Natural history of tay-sachs disease in sheep. Molecular Genetics and Metabolism, 134:164-174, Sep 2021. URL: https://doi.org/10.1016/j.ymgme.2021.08.009, doi:10.1016/j.ymgme.2021.08.009. This article has 13 citations and is from a peer-reviewed journal.
(ashiri2023usinganengineered pages 129-133): M Ashiri. Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of tay-sachs disease. Unknown journal, 2023.
(picache2022therapeuticstrategiesfor pages 6-8): Jaqueline A. Picache, Wei Zheng, and Catherine Z. Chen. Therapeutic strategies for tay-sachs disease. Frontiers in Pharmacology, Jul 2022. URL: https://doi.org/10.3389/fphar.2022.906647, doi:10.3389/fphar.2022.906647. This article has 40 citations.
(gonzalezsanchez2025advancesindiagnosis pages 11-12): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.
(taghian2025fiveyearanalysisof pages 1-2): Toloo Taghian, Jillian Gallagher, Stephanie Bertrand, William C. Baker, Kalajan Lopez Mercado, Hector R. Benatti, Erin Hall, Yvette Lopez, Abigail McElroy, John T. McCarthy, Sanjana Pulaparthi, Deborah Fernau, Samuel Mather, Sophia Esteves, Elise Diffie, Amanda Gross, Hannah G. Lahey, Xuntian Jiang, Elizabeth Parsley, Rachael Gately, Rachel Prestigiacomo, Siauna Johnson, Amanda Taylor, Lindsey Bierfeldt, Susan Tuominen, Jennifer Koehler, Guangping Gao, Jun Xie, Qin Su, Robert King, Matthew J. Gounis, Vania Anagnostakou, Ajit Puri, Ana Rita Batista, Miguel Sena-Esteves, Douglas R. Martin, and Heather Gray-Edwards. Five-year analysis of efficacy and safety of a bidirectional aav gene therapy in tay-sachs sheep. Journal of Clinical Investigation, Sep 2025. URL: https://doi.org/10.1172/jci182942, doi:10.1172/jci182942. This article has 0 citations and is from a highest quality peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Subtypes

Mechanistic Hypotheses

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Tay–Sachs Disease (HEXA-related GM2 gangliosidosis variant B): Disease Characteristics Research Report

Target Disease

1. Disease information

Concise overview (current understanding)

Key identifiers, synonyms, and alternative names

Evidence provenance

2. Etiology

Disease causal factors

Risk factors

Protective factors

Gene–environment interactions

3. Phenotypes

Phenotype spectrum and HPO mapping

Quality-of-life impact (late-onset disease)

4. Genetic / molecular information

Causal gene(s)

Pathogenic variants (examples and variant types)

Functional consequences

Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

Core biochemical defect and causal chain

Neuroinflammation and glial involvement

Myelin/oligodendrocyte involvement and biomarker data (large animal model)

Developmental stage mechanisms (human fetal brain)

Suggested ontology terms

7. Anatomical structures affected

Organ/system level

Tissue/cell level

Subcellular level

Suggested anatomical ontology terms

8. Temporal development

9. Inheritance and population

10. Diagnostics

Real-world diagnostic implementation notes

11. Outcome / prognosis

12. Treatment

Key recent developments (prioritizing 2023–2024 sources)

Human gene therapy evidence (first-in-human)

MAXO term suggestions (examples)

13. Prevention

14. Other species / natural disease

15. Model organisms

Limitations of this report (evidence availability)